





IMMUNE PROTECTION FROM LETHAL MURINE CYTOMEGALOVIRUS
INFECTION FOLLOWING LETHAL DOSE IRRADIATION AND SYNGENEIC
COTRANSPLANTATION OF EITHER COMMON LYMPHOCYTE PROGENI-
TORS OR LYMPH NODE CELLS WITH HEMATOPOIETIC STEM CELLS.
Brown JM, BitMansour A, Mocarski ES, Akashi K, Weissman IL,
Stanford University School of Medicine, Stanford, California
The Lin-IL-7R+thy-1-Scal10cKit10 population from adult mouse
bone marrow possesses a rapid lymphoid restricted reconstitution
capacity in vivo. This study is designed to evaluate the ability of
these common lymphocyte progenitor cells (CLP) and unfraction-
ated lymph node (LN) cells to functionally reconstitute immune
response to viral challenge. CLP were sorted using IL-7R( expres-
sion and conventional markers including Lin, Thy1.1, Sca-1, and
cKit. Lethally irradiated (920 rad) C57B1/Ka-Thy1.1 male mice,
8-12 weeks of age, were reconstituted with either (1) 200 syngeneic
hematopoietic stem cells (HSC); (2) 200 HSC and 1 x 107 LN cells;
or (3) 200 HSC and 3000 CLP. These mice were challenged on
Day +14 post-transplantation 5.0 x 105 plaque forming units ip of a
lacZ-tagged murine cytomegalovirus (MCMV RM427). On Day
+35, the peripheral blood of all surviving mice was analyzed using
FACS which conﬁrmed the proliferation of T and B cell popula-
tions in the mice cotransplanted with CLP. The cotransplantation
of CLP or LN cells with HSC conferred a survival advantage fol-
lowing early viral challenge when compared to mice receiving HSC
alone (p<0.09 and p<0.037, respectively).
TWO-YEAR RESULTS OF A PHASE III STUDY COMPARING
TACROLIMUS AND CYCLOSPORINE FOR GVHD PROPHYLAXIS IN
UNRELATED DONOR BONE MARROW TRANSPLANTATION.
J. Antin1, R. Nash2, C. Karanes3, J. Fay4, B. Avalos5, A. Yeager6, D. Przepiorka7,
S. Davies8, F. Petersen9, C. Anasetti1, R. Storb1, V. Ratanatharathorn10. 1Brigham
Women’s Hospital, Boston, MA. 2Fred Hutchinson Cancer Research Center, Seattle,
WA. 3Wayne State/Harper Hospital, Detroit, MI. 4Baylor U Medical Center, Dal-
las, TX. 5U of Ohio Columbus, OH. 6Emory U, Atlanta, GA. 7Texas Children’s
Hospital, Houston, TX. 8U of Minnesota, Minneapolis, MN. 9U of Utah, Salt Lake
City, UT. 10U of Michigan, Ann Arbor, MI
A total of 180 patients were enrolled in a Phase III randomized
trial comparing tacrolimus and cyclosporine in combination with
short course methotrexate for the prophylaxis on acute GVHD fol-
lowing unrelated donor bone marrow transplantation from March
1995 through September 1996. Randomization was stratiﬁed on
the degree of HLA match between donor and recipient (complete
match vs. one antigen mismatch). Ninety patients were randomized
to each treatment arm. Kaplan-Meier 100 day estimates of acute
GVHD (censoring for relapse, death and second transplant) and
two year estimates of chronic GVHD, relapse free survival and
overall survival are as follows:
Tacrolimus Cyclosporine pValue
Acute GVHD (100 days) 56% 74% 0.0002
Chronic GVHD (2 year) 76% 69% 0.96
Relapse free survival (2 year) 47% 42% 0.57
Overall survival (2 year) 54% 50% 0.46
Chronic GVHD rates between the two groups were comparable,
23 patients and 22 patients in the tacrolimus and cyclosporine arm
respectively had limited chronic GVHD while 15 patients and 13
patients had extensive chronic GVHD. These results show that
tacrolimus is more effective than cyclosporine for prevention of
acute GVHD without an increased risk of relapse or death and
show similar chronic GVHD rates.
IV BUSULFAN, CYCLOPHOSPHAMIDE (BUCY) AND HEMOPOIETIC
STEM CELLS FOR NON-HODGKIN LYMPHOMAS (NHL).
BS Andersson, H Fernandez, P Cagnoni, R Jones, V Gian, J Wingard, S Taranto-
lo, A Kashyap, SJ Forman, WW Hu, K McWilliams, H Tran, F Cabanillas, RE
Champlin, UT MD Anderson Cancer Ctr, Houston TX, U Miami, Miami, FL, U
Colorado, Denver, CO, UF Shands Cancer Center, Gainesville, FL, U Nebraska,
Omaha, NE, City of Hope Natl. Med. Ctr, Duarte, CA, Stanford U. Medical Cen-
ter, Palo Alto, CA
Oral Bu and Cy as pretransplant conditioning therapy is not used to a major
extent for malignant lymphomas. It carries a high risk for lethal liver toxicity
from unpredictable oral Bu bioavailability. We have now designed a parenter-
al Bu formulation (BusulfexTM), which is being used as conditioning therapy
prior to stem cell transplantation (HSCT). This is part of an ongoing phase II
(autologous and allogeneic) HSCT study with eligibility open to NHL
patients. Bu was given at 0.8 mg/kg every 6 hrs  16 doses, followed by Cy 60
mg/kg daily for 2 days. As part of this study, we treated 16 NHL patients (9
males/ 7 females), with a median age of 44 years (range 22-60 years). The fol-
low-up of all patients ranged from 3 months to 22months. Twelve of the 16
received the treatment as their ﬁrst transplant. Of these twelve, one was in a
second remission and remains in CR at 16 months. Three relapsing patients
were untested (1), or had chemotherapy-sensitive disease (2); all three are in
clinical CR from 9-22 months. Eight of these twelve patients were either pri-
mary refractory, or had a chemotherapy refractory relapse prior to HSCT,
and all eight attained a clinical remission. Four of these 8 have suffered pro-
gressive disease at 4.5, 9, 9.5 and 15 months, and one patient died from pneu-
monia and pulmonary hemorrhage at 2.5 mos. One year progression free sur-
vival for all patients who had a ﬁrst transplant is projected to 55%. Four of
the 16 patients had received a prior transplant, and had active disease at the
time of their second transplant. Three of these four patients have relapsed
(range 2-22 mos) and one died early (1 mo) from Aspergillus pneumonia.
The most common early (3 months) treatment-related toxicity was grade
II-III mucositis. Importantly, no patient died from veno-occlusive disease
and there was no neurotoxicity recorded. Pharmacokinetic analysis showed
signiﬁcantly less interindividual variations in AUC:s than what is seen with
oral busulfan.
We conclude, that this iv Busulfan formulation (BusulfexTM) is well tolerat-
ed, with an impressive toxicity proﬁle, and we suggest that it should be con-
sidered for further testing in pretransplant conditioning therapy prior to
HSCT for patients with high-risk Non-Hodgkin lymphomas.
CLINICAL CHARACTERISTICS OF DE NOVO AND QUIESCENT CHRONIC
GRAFT-VERSUS-HOST DISEASE IN JAPANESE PATIENT AFTER ALLO-
GENEIC BONE MARROW TRANSPLANTATION.
A. Asahi, S. Okamoto, T. Mori, R. Watanabe, and Y. Ikeda. Keio BMT Program, Div.
of Hematology, Keio University, School of Medicine, Tokyo, Japan
Chronic graft-versus-host disease (CGVHD) is a major complication fol-
lowing allogeneic stem cell transplantation. The incidence and clinical charac-
teristics of CGVHD in transplant recipients receiving contemporary
immunosuppressants are not well described in detail. To address this ques-
tion, we prospectively investigated the clinical characteristics of de novo and
quiescent CGVHD in Japanese transplant recipients.
Between January 1990 and December 1997, 113 patients with various
hematologic disorders underwent allogeneic boe marrow transplantation at
the Keio BMT Program. Among them 90 surviving 70 days or more post-
transplant with sustained engraftment were enrolled into this study. All
patients received T-cell non-depleted marrow from either HLA-matched sib-
ling or unrelated donors. GVHD prophylaxis was attempted with
cyclosporine or tacrolimus with short-term methotrexate. Immunosuppres-
sants were tapered around day 50 and discontinued around day 180. The
diagnosis of CGVHD was based upon both clinical and histological ﬁndings
characteristic of CGVHD and exclusion of other causes.
The incidence of de novo and quiescent CGVHD was 51% (46/90) (14.4%
de novo, and 36.7% quiescent). The median day of diagnosis of CGVHD was
155 days posttransplant ranging from 54 to 900 days. Mouth was most fre-
quently affected (67.4%) followed by eye (55.8%), liver (51.2%), lungs
(34.9%) and skin (32.6%). GI tract was affected in only one patient. Although
two or more organs were affected in most cases, CGVHD in a single organ
was also observed in 7-14% of cases (skin 7.1%, mouth 10.3%, lung 13.4%,
eye 12.5%, liver 13.6%). Higher age of the patient, preceding acute GVHD,
and the type of graft (sibling vs. unrelated donor) did not associate with high-
er incidence of CGVHD. With respect to the treatment, a complete response
was observed most frequently in mouth GVHD (72.4%) followed by liver
(68.2%), lungs (53.3%), skin (57.1%) and eyes (20.8%). The overall survival
and event-free survival did not differ signiﬁcantly in patients with or without
de novo and quiescent CGVHD. However, de novo and quiescent CGVHD
had signiﬁcantly affected the quality of life within one year after transplanta-
tion. Our observations on CGVHD somewhat differ from previous reports in
the western countries, and these differences may be attributable to differing
genetic backgrounds between Japanese and western populations.
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OUTPATIENT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT) FOLLOWING SHORT COURSE VAD IN MULTIPLE
MYELOMA(MM).
M.R. Trus, L. Bordeleau, C. Bredeson, I. Bence-Bruckler, S. McDiarmid, L. Huebsch,
H. Atkins, Ottawa Hospital Blood and Marrow Transplant Programme, Ottawa
We hypothesize that myeloablative therapy is more important for
control of multiple myeloma than conventional chemotherapy and
that equivalent disease control can be achieved with less
chemotherapy if followed by transplantation. Also the transplanta-
tion can be performed safely in the outpatient setting.
A retrospective review of consecutive patients (pts) with at least
Stage II multiple myeloma referred for autoHSCT was undertak-
en. A total of 42 pts were referred for autoHSCT, 6 pts were pre-
cluded because of co-morbid illnesses. The pts received a median
of 3 cycles of VAD chemotherapy. Six pts did not respond to VAD.
All treatments were performed as outpatients with patients admit-
ted to hospital only for medical complications.
Pts required a median of 2 PBSC collections. One death from
sepsis occurred during cyclophosphamide induced pancytopenia. A
total of 35 pts underwent autoHSCT between March 1994 and Jan-
uary 1998. Most (91.4%) received myeloablative therapy consisting
of melphalan 140 mg/m2, etoposide 60 mg/kg and 1x 500cGy total
body irradiation. Median time to engraftment for neutrophils was
10 days and platelets was 11 days. A median of 9 days was spent in
the outpatient transplant unit and 17 days as inpatients. Nine pts
(26%) suffered Grade 2-4 Bearman regimen related toxicity (RRT)
and there were 2 deaths from RRT. CR was obtained in 12 pts
(36%), a VGPR in 8 pts (24%), a PR in 12 pts (36%) and 1 patient
had stable disease (3%). Seven pts relapsed (21%) and 2 pts (6%)
have died during the follow up period. The median follow up from
diagnosis was 75.8 weeks and 43.3 weeks from transplant. The
relapse free survival from diagnosis was 73% at 2 years and 85% at
40 weeks post transplant. The overall survival from diagnosis was
90% at 2 years and 94% at 40 weeks post transplant.
The response rates are similar to other groups’ experiences. This
protocol is as effective as a larger number of cycles of standard dose
chemotherapy followed by autoHSCT in the treatment of MM.
PROLONGED ERYTHROID APLASIA AFTER MAJOR ABO-MISMATCHED
TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA.
Jean M. Connors, Siobhan Mc Gurk, W. Hallowell Churchill, Joseph H.
Antin, Richard J. Benjamin. Dana Farber /Partners Cancer Care and
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
The effect of graft ABO-blood group mismatch on erythroid
engraftment after allogeneic bone marrow transplant (BMT) for
chronic myelogenous leukemia (CML) is investigated.
Transfusion requirements and engraftment parameters were
reviewed for 112 patients with stable (110) or accelerated (2) phase
CML receiving related (60) or matched-unrelated (52), non T-cell
depleted BMT over a 3.5 year period.
Twenty-two of 76 evaluable patients were transplanted over an
ABO major-mismatch compatibility barrier. These patients showed
a signiﬁcantly increased delay in erythroid engraftment and in time
to RBC transfusion independence when compared with ABO-identi-
cal or minor-mismatched recipients. No difference in granulocyte or
platelet engraftment was evident. Erythroid engraftment usually
occurred spontaneously without speciﬁc intervention. One patient
was found to have erythroid hypoplasia at day 201 after BMT despite
therapy with intravenous immunoglobulin and high dose erythropoi-
etin. An anti-A titer of 16,000 was documented. This patient was
successfully treated with an aggressive course of 18 plasmapheresis
procedures with replacement with donor-type plasma.
Delayed erythroid engraftment is common after non T-cell
depleted ABO major mismatched BMT in CML but rarely
requires intervention other than transfusion support. Rare cases of
refractory erythroid aplasia may be treated without additional
immunosuppression by means of aggressive plasma exchange with
donor-type plasma.
REMOBILIZATION OF PATIENTS WITH INADEQUATE INITIAL PROGEN-
ITOR CELL COLLECTIONS FOR AUTOLOGOUS TRANSPLANTATION.
A. Bashey, S. Corringham, P. Holman, E. Carrier, D. Ward, A.D. Ho, T.A.
Lane, E.D. Ball and P. Law. Blood and Marrow Transplantation Program, Uni-
versity of California, San Diego, La Jolla, CA
A majority of patients undergoing autologous peripheral blood
progenitor cell (PBPC) transplantation achieve target CD34+ cell
dose in a single series of mobilization and leukaphereses (LP). We
analyzed 21 consecutive patients that failed to provide an adequate
collection (>3 x 106 CD34 cells/kg) who then underwent a second
mobilization a median of 15 days later (range 12-196 days). Initial
mobilization consisted of G-CSF alone (10 µg/kg/day) (n=10),
chemotherapy + G-CSF (8), chemotherapy + GM-CSF (2). Regi-
mens for second mobilization were G-CSF + GM-CSF (10 µg/kg/d
each) (12), chemotherapy + G-CSF (3), G-CSF only (20 µg/kg/d)
(3). Median numbers of LPs performed with the ﬁrst and second
mobilizations were the same (median = 4, range 2-5). Fifteen patients
achieved the target CD34+ cell dose after the second collection. In 6
patients, the total collected CD34+ cells were insufﬁcient for autolo-
gous transplantation. Mean CD34+ cells/kg/LP collection was higher
for the second mobilization procedure (2.85x105/kg vs. 5.52x105/kg,
p=0.015) as was the total WBC/kg/LP collection (1.98x108/kg vs.
3.40x106/kg, p=0.004). For the 12 patients undergoing second mobi-
lization with the G-CSF+GM-CSF combination, the CD34+
cell/kg/LP collection (4.94x105 vs. 2.53x105, p=0.083) and the total
WBC/kg/LP collection (3.88x108 vs. 2.17x108, p=0.014) were
greater than those achieved in the ﬁrst mobilization (G-CSF alone 7,
chemotherapy + G-CSF 5). A second mobilization procedure is
effective in facilitating adequate PBPC collection in the majority of
patients who fail to provide an adequate collection with the ﬁrst
mobilization. In this patient population, second mobilization using a
G-CSF + GM-CSF combination appears to produce a larger prog-
enitor cell yield than the initial mobilizing regimen. This effect may
be related to the increased total dose of growth factor or a synergy
between the growth factors. Agents with known synergy to G-CSF,
e.g., stem cell factor should be evaluated in this context.
RANDOMISED TRIAL OF BLOOD CELL (BC) VERSUS BONE MARROW
ALLOGENEIC TRANSPLANTATION: A STUDY FROM THE SOCIÉTÉ
FRANCAISE DE GREFFE DE MOELLE OSSEUSE.
D Blaise, M Kuentz, C Fortanier, JH Bourhis, N Milpied, JP Jouet, N
Fégueux, JM Boiron, P Bordigoni, L Sutton, M Attal, MP Schuller, F
Guilhot, M Legros, JY Cahn, JP Moatti and M Michallet for the SFGM,
Institut Paoli-Calmettes, Marseilles, France
We report a prospective multicentre randomised trial to compare
allo BCT or allo BMT. Pts were randomised in 2 groups: in the BCT
group, donor were collected by cytapheresis after priming with gly-
cosaled (Lenograstim kindly provided by Laboratoire Rhône Poulenc
Rorer, Montrouge) GCSF; in the BMT group, BM was aspirated
under general anaesthesia. Pts did not receive G-CSF after transplant.
Standard procedures for transplantation were used. 51 pts (37 ± 4;
M/F = 26/25) with early leukaemia (AML=24; ALL=10; CML=17)
are analysable (BCT=27; BMT=24). All donors (age: 40 (20-60);
M/F=27/24) were HLA A,B,DR matched siblings. Groups were bal-
anced for patient, donor and transplant characteristics. BC harvest led
to the collection of a higher number of CD34+ and CD3+ cells than
BM harvest (p=0.004 and p<0.001). Time to reach 0.5 and 1 x 109/1
neutrophils was 5 and 3 days shorter in BCT group (p=0.007 and
p=0.004). Pts in the BCT group reached 25 and 50 x 109/l platelets 10
and 18 days earlier (p=0.005 and p<0.001). This led to fewer platelet
transfusions during the 180 ﬁrst days post transplant (4 transfusions
vs. 12 transfusions: p=0.001). This quicker haematological recovery
was associated with a shorter hospitalisation duration. AGVHD was
not increased nor CGVHD with this follow-up. Fifteen month prob-
abilities of relapse and survival are not different. In addition, prospec-
tive and comparative economic evaluation of the ﬁrst 6 months after
transplant was performed. This haematological beneﬁt was associated
with a 20% decrease in the cost of the procedure over the ﬁrst 6
months. Allo BCT leads to a dramatic improvement of both platelet
and neutrophil reconstitution with absence short-term adverse effects
for donors or any impairment to patient outcome.





OUTPATIENT MANAGEMENT AFTER BONE MARROW TRANSPLANTATION.
Melo. T.S.; Neves, M.L.; Pinheiro, C.T.; Torres, R.C.; Bouzas, 
L.F.; Tavares, R.C.; Tabak, D.G. Bone Marrow Transplantation Unit
(CEMO), Instituto Nacional de Cancer, Rio de Janeiro, RJ, Brazil
Technological advances resulted in an increasing number of
patients submitted to bone marrow transplantation (BMT) with a
favorable outcome. The existance of adequate facilities and person-
nel can contribute to the reduction of complications. Here we
compare distinct periods of outpatient follow up in our Unit after
the establishment of a complete ambulatory care department.
Patients (pts) were evaluated in 3 different periods: 25 pts from
4/93 - 3/94 (1st); 36 pts from 4/95 - 3/96 (2nd) and 60 pts from
4/97 - 3/98 (3rd). Initially, the outpatient clinic included only
ofﬁces. On the 2nd period, an enlarged facility was created and on
the 3rd period new personnel was trained and special care was
delivered to pts and family members. In the 1st period, hospital dis-
charge occurred a median of 30d after BMT (14-99), in the 2nd
period 24d (10-71) and 22d (10-85) on the 3rd period. Only 4% of
the pts were discharged prior to day 20 on the 1st period while
22.2% and 36.7% left the hospital prior to day 20 respectively on
the 2nd and 3rd periods. Readmissions were more frequent on the
1st and 2nd periods when compared to the 3rd period (80% x 61%
x 36%, respectively). The major cause of readmissions were infec-
tions (25% x 50% x 22.7%) and metabolic/gastrointestinal distur-
bances (30% x 36.5% x 31.8%), respectively in 1st, 2nd, 3rd peri-
ods. Prior to transplantation only 16.7% of the pts were admitted
on the 3rd period when compared to 56% and 47.2% respectively
in the 1st and 2nd periods. We have demonstrated our ability to
improve our hospital stay through adequate nursing care in a spe-
cial outpatient facility for patients submitted to BMT. Our analysis
of cost reduction is underway.
SAFETY OF AUTOLOGOUS STEM CELLS TRANSFECTED WITH REVM10
INFUSED INTO HIV+ PATIENTS WITH CD4+ CELL COUNTS < 500 AFTER
CONDITIONING WITH CYCLOPHOSPHAMIDE.
M.Carabasi, S.Deresinski, P.Bucy, A.Tilden, G.Shaw, S.Jackson, C.Kemper, T.
Martin, and K.Squires
University of Alabama, Birmingham, Birmingham, AL, AIDS Community
Research Consortium, Redwood City, CA, and SyStemix, Palo Alto, CA.
We have conducted a phase I study using autologous stem cells transfected
with RevM10, a transdominant mutant of the HIV gene Rev that confers
resistance to HIV. Transduced stem cells were infused into 24 HIV+ patients
(pts) with CD4+ counts < 500. All pts were age 18 yrs or older, were on no or
stable anti-retroviral therapy for 30 days prior to enrollment, had suitable
I.V. access, and demonstrated adequate marrow and other organ function
prior to treatment. Pts with concurrent malignancy, serious opportunistic
infection, or receiving other immunomodulating agents or anti-retrovirals
not covered by IND were excluded. Pheresis products were collected via
peripheral venous access in a single session after mobilization with G-CSF.
11 pts (5 with CD4+ counts between 100 and 500, 6 with CD4+ counts <
100) were treated with transduced stem cells alone. 13 pts with CD4+ counts
between 100 and 500 received cyclophosphamide (Cy) (1.2g/m2 - 5pts,
1.8g/m2 - 5pts, and 2.4g/m2 - 3pts) prior to transduced stem cell infusion. All
pts experienced fevers and myalgias due to G-CSF during mobilization. 9
pts, including 6 in the two highest dose Cy cohorts, became neutropenic
after treatment with Cy, and 2 pts developed febrile neutropenia. All pts
recovered uneventfully. Viral burden has been monitored in 19 pts for at
least 3 mos., with 18/19 followed for 6 mos. No signiﬁcant impact on viral
burden has been detected, although no data are yet available on pts receiving
the highest CY dose. In addition, no change has been seen in the absolute
CD4+ cell count in any group, including 3 pts treated with the highest dose
of Cy. Analysis of T and B cell function is ongoing. To date, transient low-
level marking has been seen in PBMC assayed post-infusion in 2 of 3 pts
treated with the highest dose of Cy. We conclude that autologous stem cells
transfected with RevM10 can be safely used alone in HIV+ pts with very low
(<100) CD4+ counts, or in combination with CY in pts with CD4+ counts
between 100 and 500. Whether higher levels of marking can be obtained
with more aggressive conditioning or different gene constructs is being
investigated.
DMSO IS NOT TOXIC TO HEMATOPOIETIC STEM CELLS.
R. Buckstein, K. Imrie, D. Spaner*, M. Reis, P.Pinkerton*, I. Dube, A. Coovadia*, JB. Robin-
son*, S. Nanji*, P. Richardson*, A. Lima*, K. Hewitt* and NL. Berinstein. Toronto Sunnybrook
Regional Cancer Centre. Toronto, Ontario
Purpose: We evaluated the role of ‘slow’ stem cell infusions in mitigat-
ing the adverse side effects often attributed to the DMSO during ‘bolus’
injections. We determined the safety, efﬁcacy and toxicity of this approach
by measuring colony count formation, CD34+ counts, and viability of
samples extracted from the ﬁrst bag of stem cell graft. We also assessed
patient symptoms during extended stem cell infusion times and the times
to neutrophil engraftment and platelet transfusion independence. Meth-
ods: 5 consecutive patients who received high dose CBV chemotherapy
followed by autologous stem cell transplant for relapsed follicular lym-
phoma were evaluated. Stem cells were collected via large volume
leukapharesis and cryopreserved 1:1 in 20% DMSO, 10% plasma and
70% plasmalyte at -152oC. On the day of transplant, patients were pre-
medicated with Solucortef, Benadryl, Ondansetron and Ativan. Stem cell
bags were consecutively thawed, diluted with ACDA 20% of total volume
and infused by a nurse. Three samples of 2 ml each were withdrawn from
the ﬁrst bag of thawed stem cells and at room temperature exposure times
of 0,30 and 60 mins, the samples were washed once, resuspended and cells
counted. Viability was measured by trypan blue exclusion. CD34% enu-
meration was by flow cytometry using ISHAGE guidelines. Cells were
plated in triplicate at standard concentration in semisolid methylcellulose
pre-tested anchorage independent culture dishes, and incubated for 10-14
days at 37oC in a 5% CO2 environment. Progenitor cell enumeration was
by standard criteria. Results: The median number of bags infused per
patient was 3, with a median volume of 170 ml, a median total infusion
time of 72 minutes and a median infusion rate of 2.67 ml/minute. Patients
were largely asymptomatic during infusion.
Time 0 30 60 p
CFU-GM 41 56 34 NS
BFU-E 46 75 57 NS
CD34% .23 .27 .21 NS
Viability% 71 73 75 NS
Median time to neutrophil engraftment was 11 days and 10 days to platelet
independence.
Conclusion: A slower infusion of thawed stem cells is well tolerated, easily
administered by nursing personnel and does not compromise engraftment
rates, CD34% and progenitor cell counts or cell viability. Our study sup-
ports the routine use of slow infusions in stem cell autografting.
AUTOLOGOUS STEM CELLS TRANSPLANT (ASCTX) AFTER ASSISTED
MECHANICAL VENTILATION (AMV) FOR ADULT RESPIRATORY DIS-
TRESS SYNDROME (ARDS).
Canepa C., Orlando S., Saba S., Marino A., Nascimbene G., Godoy G.,
Mykietiuk A.BMT Unit, CUCAIBA, La Plata, Argentina.
Purpose.. To evaluate patients response to ASCTx that previous-
ly required AMV for ARDS.
Materials And Methods.. Retrospective analysis of clinical
records and ﬁles of oncohaematology patients to establish the num-
ber of patients who underwent ASCTx that previously required
AMV for more than 24 hs due to ARDS. The AMV was carried
out at the BMT unit of C.U.C.A.I.B.A., La Plata, Argentina, with
our medical staff under strict isolation.
Results.. During the period 6/1994 to 10/1998, 92 patients were
subject to ASCTx; only two of them required AMV due to ARDS.
Both patients suffered from A.M.L. and required AMV as a conse-
quence of neutrophenic episodes, fever, and sepsis, with blood cul-
tures positive to Streptococus viridans. Both patients recovered
from their ARDS and later underwent ASCTx. At the time of
update (98/10/31) both patients showed complete remission (CR)
at +610 and +836 days, respectively.
Comments. AMV allowed these patients to be subject to
ASCTx, be disease-free and in continous CR after +610 and +836
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CORD BLOOD TRANSPLANTATION FOR PAEDIATRIC HAEMA-
TOLOGLCAL DLSORDERS : THE HONG KONG EXPERIENCE
GCF Chan1, SY Ha1, TL Lee1, MHY Tang2, RHS Liang3, YL
Lau1.Departments of Paediatrics1, Obstetrics2 & Medicine3, Queen
Mary Hospital, The University of Hong Kong, Hong Kong, China
Objectives : To review our early experience of using cord blood trans-
plantation (CBT) for the treatment of various types of childhood haemato-
logical disorders.
Methods : From Dec. 94 to Nov. 98 a total of 5 cases of CBT was per-
formed in our hospital. Four patients had transfusion dependent thalassaemia
(Thal)(( thalassaemia major n=2, haemoglobin Bart disease n=1, ( thalas-
saemia/haemoglobin E n=1) and one patient had acute T-lymphoblastic
leukaemia (ALL) in second remission. The conditioning regimen was
Bu20/Cyc200/ATG90 for the Thal (all Thal patients were less than 3 years
old) and VP16(50)/Cyc100/TBI(12) for the ALL patient. The graft vs host
(GVHD) prophylaxis was cyclosporin A & methotrexate. Results: The 4
Thal patients received sibling HLA-matched CBT (one case of 1-Ag mis-
matched) and the leukaemic patient received HLA-matched unrelated donor
(MUD) CBT. T-cell depletion was not performed. The median age of the
recipients was 2.8 yrs (range: 2.2 to 10 yrs). The median cord blood volume
was 64ml (range 30-81ml). The median MNC was 5 (range 0.87-
11.4)x107/Kg & the median CFU-GM was 2.2 (range 1.01-7.6)x104/Kg. All
patients engrafted (neutrophil > 0.5x109/L for 2 consecutive days) and the
median duration of engraftment was 24 days (range : 16 to 27 days). Four of
them received G-CSF augmentation prior to engraftment. The median
engraftment time for platelet (Plt>50x109/L) was 38 days (33-56 days). Three
patients developed acute GVHD (grade 2 to 3) but mainly affecting the skin
and responded to short course of pulse steroid treatment very well. The
chimeric study by serial karyotyping on the 3 sex mismatched cases showed
100% donor cells after transplant. All Thal patients became transfusion inde-
pendent and their median follow-up time was 15.5 months (range: 4 mos to
4 yrs). The leukaemic patient showed no sign of relapse but the follow-up
time is still short. Conclusions: CBT is a feasible and reliable alternative for
bone marrow transplantation. There is no increase in rejection noted in tha-
lassaemia patients who underwent CBT. Similar to others ﬁnding, GVHD
seems to be less severe and extensive in CBT as shown in our I-Ag mis-
matched and MUD cases.
PHASE I STUDY OF HIGH-DOSE TOPOTECAN AND ALKYLATING
AGENTS FOR ADVANCED OVARIAN CANCER.
M. Donato D. Gershenson, J.T. Wharton, A. Aleman, C. Ippoliti, D.
Bodurka, C. Levenback, M. Bevers, J. Wolf, R. Freedman, J. Gajweski, R.
Bast and R.E. Champlin. M.D. Anderson, Cancer Center, Houston TX.
Topotecan (TOPO) is a promising agent for platinum refractory ovarian
cancer (CA) but its use in combination is limited by myelosuppression. The
purpose of this study was to establish the maximum tolerated dose (MTD) of
TOPO when used with alkylating agents followed by peripheral blood stem
cells (PBSC). 22 patients (pts) with advanced ovarian CA received a total of
26 cycles of TOPO with cyclophosphamide (CY) and melphalan (MEL) fol-
lowed by PBSC. Pts received TOPO over 30 min daily on days(d) -6 to -2;
CY 1 g/m2/d d -6, -5, -4 and MEL 70 mg/m2/d d -3, -2. PBSC were infused
on d 0 with G-CSF. Median age was 45(21-61). Disease status pre-trans-
plant: chemoresistant with PD(6 pts), relapsed disease in PR(7 pts), positive
2nd look(7 pts), (2nd CR(2 pts). 4pts had ( 1 prior carboplatin-based trans-
plant. Toxicity using the Bearman scale, was limited to grade 2 mucositis and
diarrhea in a total of 6 and 2 pts respectively, at dose levels 1, 4, 6. Engraft-
ment kinetics did not vary with dose levels. Median time to neutrophils (
0.5x109/(L was 9 days (8-11) and platelets ( 50 x 109/(L: 14days (7-24).
DOSE LEVEL 1 2 3 4 5 6 7
TOPO
mg/m2/d 1.25 1.5 1.75 2.0 2.25
2.5 2.75
Number
of pts. 2 3 3 3 5 9 1
55% of the cycles were associated with neutropenic fever. Disease status
post transplant: 76%CR, 19%PR, 5%SD. Overall response rate for patients
with measurable disease which includes all the chemoresistant pts. was
91.7%. In conclusion, the TOPO, CY and MEL combination is a promising
new regimen, feasible in heavily pretreated pts. Non-hematological toxicity
of TOPO was minimal and the MTD has not yet been established. The reg-
imen was very active and a phase II study should follow.
ABX-CBL FOR THE TREATMENT OF STEROID REFRACTORY ACUTE
GRAFT-VERSUS-HOST DISEASE (GVHD).
H.J. Deeg, B. Bolwell, G. Long, F. Schuening, R. Rifkin, J. Cunningham, B. Blazar,
T. Furlong, N. Havrilla, J. Lipani. Fred Hutchinson Cancer Research Center, Seat-
tle, WA; The Cleveland Clinic, Cleveland, OH; Duke University, Durham, NC;
University of Wisconsin, Madison, WI; Rocky Mountain Cancer Center, Denver,
CO; University of Minnesota, Minneapolis, MN; and Abgenix, Inc., Fremont, CA
Allogeneic marrow ansplant recipients who develop acute GVHD despite
GVHD prophylaxis generally receive ﬁrst-line therapy with glucocorticoids.
However, with this “standard” treatment, complete responses are achieved in
only 20-25% of patients, thus, the majority of patients require additional
therapy. Monoclonal antibody (MAB) ABX-CBL is a murine IgM, reactive
with activated T, B and NK cells, and recently shown to be directed at
CD147. In pilot studies, this MAB had activity in the treatment of rejection of
renal allografts and in children with steroid-refractory GVHD. The present
dose escalation trial started at 0.01 mg of ABX-CBL/kg, escalating over 0.1 to
0.3 to 1.0 mg/kg given daily for 7 days and for four additional doses over the
ensuing 2 weeks. At seven transplant centers, 26 patients have been enrolled.
Patient age ranges from 1 to 46 (median 35) years; 17 patients were male and
nine female. The underlying diagnoses included acute or chronic leukemia,
lymphoma and myelodysplasia. The donor was related (HLA-identical or one
antigen mismatched) in 13 and unrelated in 13 cases. The extent of GVHD at
the time of enrollment included skin involvement only in ﬁve, liver only in
one, and various combinations of skin, intestinal and hepatic involvement in
the remaining patients. Eight patients given 0.01 mg/kg (anticipated to be
non-effective), and six patients given doses of 0.1 mg/kg experienced no side
effects. Of the subsequent six patients given 0.3 mg/kg, three developed
severe muscle cramping which was considered dose-limiting toxicity. Thus
the dose was de-escalated to 0.2 mg/kg and six patients were treated at that
level. Overall, 15 of 26 patients (13 of 18 given ( 0.1 mg/kg) had clinical
responses, including two partial responses at 0.01 mg/kg. In six patients,
responses were complete and no additional therapy was required. Four
patients who had responded had a ﬂare of GVHD and were retreated with
ABX-CBL at 0.3 mg/kg/day. Two had a response; in two, treatment was dis-
continued because of severe muscle pain. In conclusion, ABX-CBL offers
effective therapy of acute GVHD in steroid refractory patients. The maxi-
mum tolerated dose of antibody ABX-CBL has been identiﬁed. This MAB
warrants further investigation in allogeneic marrow transplant recipients.
CONTROL OF ASPERGILLUS PNEUMONIA WITH REPEATED DONATION
OF G-CSF ELICITED GRANULOCYTES.
Reggie E. Duerst, CN Abboud, and J Liesved, Univ Rochester, Rochester NY
Fungal infection, (esp. aspergillus), is often a contraindication to high-dose
therapy and hematopoietic stem cell rescue (HSCR). The prolonged period
of neutropenia results in great risk for progression of infection. Granulocyte
transfusions (Gran Tran) have been used as a prophylactic measure or as a
therapeutic agent for patients with proven infection and neutropenia. We
report the use of directed GranTran, from father to ABO compatible son (5
yo), following HSCR for refractory AML. Aspergillus infection was con101
ﬁrmed 3 weeks prior to HSCR by broncho-alveolar lavage (BAL). Unrelated
umbilical cord blood matched at 4 of 6 HLA antigens was used as the source
of stem cells. G-CSF was used to elicit neutrophilia in the donor, and an
apheresis product with high cell content.
Cytoreduction was comprised of fractionated total body irradiation, mel-
phalan and anti-thymocyte globulin. GVHD prophylaxis was comprised of
cyclosporin A and corticosteroids. Beginning on d 0, the father was treated
with G-CSF (480 mcg). Apheresis followed 12 hr later. The recipient
received G-CSF daily. The cell products were divided into two parts. One
portion was irradiated and infused within 6-8 hr of collection (days 1, 4, 7,
10, 14 and 17), the other was stored at 4 (C overnight, then irradiated and
infused the following day. Apheresis products contained from 4.6 to 10.4
x1010 cells. Cell doses for the recipient (17 kg) ranged from 1.35 to 3 x109
cells/kg. After initiation of the Gran Tran, the patient’s WBC was < 100/ul
only once (day +7). Because of mucositis, itraconazole was replaced by lipo-
somal amphotericin-B (lipAmB) days 12-25. G-CSF was discontinued on day
+28. CT scan on day +28 revealed clearing of the infiltrates noted pre-
HSCR. Corticosteroids were tapered off. CT scan day +77 showed redevel-
opment of inﬁltrates in the previously noted locations. Open biopsy demon-
strated aspergillus by cytology and lipAmB has been restarted.
Anti-fungal therapy and GranTran during the immediate post-HSCR
period led to improvement, but not eradication of the aspergillus pneumo-
nia. A pilot study to evaluate the feasibility of directed GranTran for patients





A SINGLE ADMINISTRATION OF R-METHUG-CSF-SD/01 (SD/01) SIG-
NIFICANTLY IMPROVES NEUTROPHIL RECOVERY FOLLOWING
AUTOLOGOUS BONE MARROW TRANSPLANTATION.
A.M. Farese, L. Roskos*, E. Cheung*, R.B. Stead, S.M. Yin*,
T.J.MacVittie. Greenebaum Cancer Center, Baltimore, MD, and
Amgen Inc, Thousand Oaks, CA
Conventional daily administration of Filgrastim is effective in reducing the duration of
severe neutropenia following myelosuppressive cytotoxic therapy or myeloablation and
stem cell transplantation. SD/01, a PEGylated form of Filgrastim (r-metHuG-CSF),
demonstrated enhanced biological and pharmacokinetic (PK properties in normal rhesus
monkeys (n=3). Following a single injection of SD/01 at 300 (g/kg, white blood cells
(WBC) and plasma SD/01 levels remained above baseline levels (BL) for 7 days. PK simu-
lations indicated that effective plasma concentrations(2.5 ng/mL based on pharmacody-
namic modeling) would be maintained for extended periods during neutropenia: therefore,
dose levels of 100 and 300 (g/kg were selected for evaluation. We investigated the ability of
SD/01 to modify neutrophil regeneration in a monkey model of bone marrow (BM)-
derived mononuclear cell (MNC) transplantation. On d0, animals were myeloablated by
total body exposure to 920 cGy, 250 kVp x-irradiation (TBI) and within 2 hours of expo-
sure were infused with 1 x 108 AuBM-MNC/kg bw. The Au-BMT controls (n=9) received
0.1% autologous serum (AS). Following myeloablation and AuBMT, SD/01 (300 (g/kg, sc,
n=4 or 100 (g/kg, sc, n=3) was administered on d1, or Filgrastim (10 (g/kg/d, sc, n=4) was
administered on a daily basis until an absolute neutrophil count (ANC) of 3,000/(L was
attained (range d12-17). Animals were clinically supported with antibiotics, fresh irradiated
whole blood and ﬂuids as needed. Bone marrow-derived clonogenic activity was evaluated
prior to and on days 7, 14, 21 and 46 post TBI and AuBMT. Plasma samples for PK analy-
sis were obtained through d11 post TBI, and complete blood counts were monitored for
50 days post TBI and AuBMT. Both SD/01 and Filgrastim significantly (P < .05)*
improved neutrophil recovery.
TREATMENT DURATION (DAYS) ANC NADIR REC TO BL ANTIBIOTICS
ANC < 500/µL (/µL) (DAY) REQUIRED(DAYS)
0.1% AS 11.1 28 21 16.9
SD/01 300 µg 3.3* 544 10 7.7
SD/01 100 µg 4.0* 389* 14 10.0
Filgrastim 6.5* 148* 13 9.3
Neither SD/O1 or Filgrastim signiﬁcantly improved platelet recovery. Effective plasma
concentrations were maintained in myelosuppressed animals until after onset of
hematopoietic recovery, consistent with self-regulating, ANC-dependent properties of
SD/01 elimination. A single dose of SD/01 is at least as effective as daily Filgrastim and
results in a signiﬁcant improvement of neutrophil recovery following myeloablation and
AuBMT in rhesus monkeys.
EX VIVO EXPANDED, RETROVLRALLY TRANSDUCED CYTOTOXIC T-
LYMPHOCYTES (CTL) ENHANCE ENGRAFTMENT OF HAPLOIDENTICAL
MARROW.
GE Georges, R Storb, JD Thompson, and RA Nash, Fred Hutchinson Cancer
Research Center and University of Washington, Seattle, WA
Using the well-established dog model of allogeneic hematopoietic
stem cell transplantation, we asked if retrovirally transduced donor
derived, recipient-speciﬁc CTL can prevent rejection of histoincompat-
ible marrow.
CTL were generated by bulk mixed lymphocyte culture between
DLA-haploidentical littermates. To track CTL following in vivo infu-
sion, we transduced CTL with the retroviral vector LGFPSN express-
ing green ﬂuorescence protein (GFP) and neoR. Following 4- week cul-
ture that included transduction, G418 selection and expansion, CTL
had 60-80% speciﬁc lysis and >99% of CTL were CD3+, >95% GFP+
and >76% were CD8+. A median CTL cell dose of 2.0x107/kg recipient
weight was infused into 7 DLA-haploidentical littermates following 9.2
Gy total body irradiation (TBI). The median unmodiﬁed marrow cell
dose infused was 4.5x108 total nucleated cells/kg or 3.9x106 CD34+/kg.
No post grafting immunosuppression was given.
Seven of 7 haploidentical recipients engrafted (ANC>500/(L, median
day +8) and platelets (>50K); all 7 recipients developed multi-organ
severe (grade IV) graft versus host disease (GVHD) confirmed by
histopathology. Fluorescence cytometric analysis of recipient peripheral
blood after transplant revealed a sharp increase in the absolute number
of circulating GFP+CTL (1.0-1.5x104/mL) on days +5 to +6, with a
subsequent rapid fall in GFP+ cells at the onset of engraftment. As con-
trols, 8 dogs received DLA-haploidentical marrow only following 9.2
Gy TBI: 2 engrafted and developed GVHD, 6 had graft rejection.
These results show that ex vivo expanded, retrovirally transduced
CTL enhance engraftment of DLA-haploidentical marrow in the set-
ting where graft rejection is expected. Future studies will test if trans-
duced CTL addback to T-cell depleted marrow can safely achieve
engraftment without GVHD using an inducible suicide gene, herpes
simplex virus thymidine kinase.
A NON-MYELOABLATIVE REGIMEN OF FLUDARABINE AND
CYCLOPHOSPHAMIDE INDUCES MIXED CHIMERISM IN AN F1-INTO-
PARENT MURINE MARROW REJECTION MODEL.
Matthew Petrus, Ronald E. Gress, and Daniel Fowler; Medical Oncology
Branch, National Cancer Institute, Bethesda, MD
Clinical evidence suggests that ﬂudarabine contributes to the preven-
tion of marrow graft rejection in the setting of non-myeloablative allo-
geneic BMT. In light of this evidence, we developed an F1-into-parent
murine marrow rejection model to evaluate factors that might optimize
this transplant strategy. Host B6 mice were treated with high-dose total
body irradiation (950 cGy), sublethal irradiation (600 cGy), or a combi-
nation of ﬂudarabine (ﬂu) and cyclophosphamide (cy) [100mg/kg/day
and 50 mg/kg/day, respectively; 18-27 days of treatment]. Compared to
recipients of 950 cGy irradiation (n=6), flu/cy recipients (n=6) had
equivalent or greater levels of lymphocyte depletion just prior to the
transplantation of T cell-depleted B6D2F1 marrow (ﬂu/cy recipients
versus TBI recipients: CD4#/spleen of 0.04M and 0.55M, p=.031;
CD8#/spleen of 0.07M and 0.46M; p=.24; CD19#/spleen of 0.32M and
0.82M; p=.17). In marked contrast, the ﬂu/cy recipients had much high-
er levels of Mac-1+ myeloid cells/spleen than recipients of 950 cGy irra-
diation (4.6M versus 0.56M, p=.03); the level of Mac-1+cells in the
flu/cy recipients was not decreased relative to untreated B6 control
mice (4.6M versus 2.9M/spleen; p=.14). Mice treated with 950 cGy
irradiation displayed a high level of F1 chimerism as determined by two
color ﬂow cytometry at day 30 post-BMT (93% F1 chimerism; n=9).
Mice given 600 cGy irradiation had very low level F1 chimerism
(3.5(0.4%, n=8); in contrast, mice treated with Flu/cy had higher levels
of F1 chimerism (8.6 ( 2.2%, n=13, p=.04). Further follow-up is
required to evaluate the long-term stability of the mixed chimerism
observed in the ﬂu/cy recipients. These data indicate that preparative
regimens containing a combination of fludarabine and cyclophos-
phamide have potential for the prevention of marrow rejection across
fully-MHC disparate barriers without myeloid ablation.
CONVERSION FROM MIXED TO ALL DONOR HEMATOPOIETIC
CHIMERISM FOLLOWING INFUSION OF MINOR HISTOCOMPATIBILITY
ANTIGEN-SPECIFIC DONOR LYMPHOCYTES IN DOGS.
GE Georges, R Storb, C Yu, B Torok-Storb, JD Thompson, B. Bruno and RA
Nash, Fred Hutchinson Cancer Research Center and University of Washington,
Seattle WA
Stable mixed hematopoietic chimerism can be established in dog
leukocyte antigen (DLA)-identical littermates following sublethal total
body irradiation (200 cGy TBI) before and immunosuppression with
mycophenolate mofetil and cyclosporine (CSP) after stem cell trans-
plantation. We asked if donor lymphocyte infusions (DLI) could be
used to convert mixed to all donor chimerism.
Eight dogs with stable mixed chimerism were given unmodiﬁed DLI
between day 36 to 414 with an infused cell dose of 1.5x107-2.0x108
CD3+cells/kg. Three received a second unmodiﬁed DLI on day 213 to
286 with 1.0x108-2.6x108 CD3+/kg. Chimerism status was assessed by
quantitative PCR phosphorimage analysis using informative microsatel-
lite markers with peripheral blood DNA, for 4-8 months after each
DLI. There was no signiﬁcant change in percent donor engraftment
following each unmodiﬁed DLI in these 8 mixed chimeras.
DLI donors were then sensitized to recipient minor histo-compatibil-
ity antigens (mHA) in vivo with weekly subcutaneous injections of
recipient skin grafts x 4. Eight mixed chimeras received mHA-speciﬁc
DLI on day 201 to 651 at a cell dose of 2.0x107-9.3x107 CD3+/kg.
Within 4 to 10 weeks after DLI, all 8 recipients converted to >95%
donor chimerism in both lymphoid and myeloid cells. Two recipients
developed grade II skin graft versus host disease (GVHD) 3 to 4 weeks
after DLI that responded to CSP treatment. One recipient developed
severe marrow aplasia without GVHD. The remaining 5 recipients had
no complications from mHA-speciﬁc DLI.
These results show that a non-myeloablative transplant regimen to
establish mixed hematopoietic chimerism provides a platform for adop-
tive immunotherapy that has clinical potential to treat patients with
malignant diseases. Conversion to all donor hematopoiesis requires
infusion of donor lymphocytes speciﬁc for host mHA.
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HYDROXYCHLOROQUINE FOR THE TREATMENT OF CHRONIC GRAFT-
VERSUS-HOST DISEASE
Andrew Gilman, Ka-Wah Chan, Mark Mogul, Christopher Morris, Fred Gold-
man, Michael Boyer, Emanuel Cirenza, Amitabha Mazumder, Richard Cahill,
Stanley Frankel, and Kirk Schultz.Children’s Mercy Hospital, Kansas City, MO,
University of Texas/MD Anderson Cancer Center, Emory University, Atlanta,
GA, University of Cincinnati, Cincinnati, OH, University of Iowa, Iowa City, IA,
Albany Medical College, Albany, NY, Georgetown University, Washington, DC,
and University of British Columbia, Vancouver, BC
A Phase II trial of hydroxychloroquine (HCQ) for chronic graft-ver-
sus-host disease (GVHD) was conducted. HCQ is a 4-aminoquinoline
antimalarial used for the treatment of autoimmune diseases. HCQ
interferes with antigen processing and presentation, cytokine produc-
tion, and cytotoxicity. Thirty-nine patients with steroid-resistant or
steroid-dependent GVHD or who were experiencing toxicity from
medications needed to control their GVHD were enrolled from 8/94 to
11/98. Patients were treated with HCQ 12 mg/kg/day (adult dose 800
mg/d) for up to 1 year after achieving target HCQ levels. Twenty-nine
patients (17 children, 12 adults) are evaluable (8 not evaluable because
of an inadequate therapeutic trial, 2 too early to evaluate). Donor type
was matched family member (16), matched unrelated donor (9), and
haploidentical family member (4). Onset of chronic GVHD was pro-
gressive (12), quiescent (14), and de novo (3). Two complete and 13 par-
tial clinical responses were seen for a response rate of 52% (15/29). All
responders also had a >50% decrease in their dose of steroids. Improve-
ment was most common in skin, oral, and hepatic involvement. Throm-
bocytopenia also often improved. There was no signiﬁcant difference in
the response rate based on the patient age, type of donor, type of onset
of GVHD, or platelet count at study entry. Thirty-eight patients are
evaluable for toxicity (one lost to follow-up). HCQ can cause visual sco-
tomata, but these rarely occur before two years of therapy. No retinal
toxicity was seen. The most common side effects were gastrointestinal
symptoms, which occurred in three patients (8%). HCQ has signiﬁcant
clinical activity for chronic GHVD. The Children’s Cancer Group is
beginning a randomized, placebo-controlled, double-blinded Phase III
trial of HCQ.
PHENOTYPIC ANALYSIS OF CD4 CELLS POST STEM CELL TRANSPLANT
(SCT): PROLONGED PERSISTENCE OF AN ACTIVATED PHENOTYPE AND
INCREASED PROPORTION OF TH 2 CELLS IN RECIPIENTS OF MATCHED
UNRELATED DONOR (MUD) STEM CELL TRANSPLANTS (SCT).
M Grimley, D Marmer, S Lee, A Filipovich. Children’s Hospital Med-
ical Center, Cincinnati, OH, USA
Animal models have shown that the balance between Th 1 and Th 2 cells can
affect the recovery of both cell-mediated and humoral immunity post SCT. We
examined the expression of activation markers (HLA-DR and Ox40) and Th2 mark-
ers (CD30+ and/or CD7-) on CD3+CD4+ T cells at various time points post SCT
using multiparametric FACS analysis on peripheral blood from SCT recipients. The
results for matched sibling donor (MSD) and matched unrelated donors (MUD) are
shown in the table. Patient results were signiﬁcantly different (p<0.05) from normal
controls except HLA-DR and Ox40 in MSD recipients at 6 mos post SCT.
CELL
SURFACE SCT NORMAL
MARKER TYPE 30 DAYS 100 DAYS 6 MONTHS CONTROLS
CD30+ MSD 1.8 +/- 1.6 1.2 +/- 0.6 0.5 +/- 0.5 0.35 +/-
0.33
MUD 2.8 +/- 1.8 2.2 +/- 1.9* 2.2 +/- 1.8*
CD7- MSD 54 +/- 25 54 +/- 19 34 +/- 23 15.6 +/-
7.7
MUD 51 +/- 10 49 +/- 18 43 +/- 24
HLADR MSD 33 +/- 13 23 +/- 12 17 +/- 2 11.1 +/-
+ 18.4
MUD 31 +/- 18 45 +/- 22* 35 +/- 22*
Ox40+ MSD 14 +/- 11 11 +/- 4.3 8.5 +/- 1.2 5.2 +/-
5.8
MUD 20 +/- 13.2 23 +/- 12.7* 17 +/- 12.5*
Data expressed as mean % expression of marker on CD4+ cells +/- 1 S.D. * = p <
0.05 comparing MUD to MSD at different time points
Recipients of MUD SCT demonstrate persistent skewing towards a Th2 pheno-
type as well as an activated CD4+ phenotype throughout the ﬁrst 6 months post
SCT. This Th2 skewing may inhibit the development of cell mediated immunity
and contribute to the delayed immunoreconstitution in recipients of MUD SCT.
EXPERIENCE WITH PERIPHERAL BLOOD STEM CELL (PBSC) TRANS-
PLANTATION IN A CENTER OF MEXICO
Gómez-Morales E, Sánchez-Valle E, Campos G, Pedraza M, Chávez G, Pizzuto-
Chávez J. Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS,
México City, México.
The goal of this work is to show our experience in the use of PBSC in
transplantation setting or their complications. Our protocol involved
the mobilization with G-CSF at dose of 10 ug/Kg/day, subcutaneously
for 5 days. PBSC were obtained with the special program of CS3000
machine. The volumen processed was 10 liters. Nine patients (pts)
underwent PBSC infusion for transplantation, 7 of them in the autolo-
gous setting and the others in the allogeneic setting. Five pts had
ANLL, 2 pts had ALL and the other two had MDS and CML respec-
tively. Median age was 30, range 17 to 50 yrs; 5 female, 4 male. PBSC
for autologous transplantation were harvested at 4oC without cryop-
reservation at long 5 days. Median MNC obtained was 6.3, range 3.8 to
13.0 x 108 MNC/Kg. Leucocyte engrafment occurred between days 14
to 24, median 21. Two pts had very slow platelet engrafment more than
100 days. Addicionally, 6 pts received PBSC for the treatment of
relapse (2 ALL), graft failure (2 AA/ 1 ANLL) or Epstein Barr virus
infection after BMT (1). The counts of MNC in this cases was similar
to the others procedures. Two pts with relapse, who received continu-
ous PBSC infusion developed pancytopenia and graft versus host dis-
ease G-IV. One pt with Epstein Barr virus infection and monoclonal
gammopathy had a good response with control of infection. Two pts
with AA had graft failure and they did not show response after PBSC
infusion. One pt with ANLL received PBSC infusion for graft failure
secondary to severe infection, she had not response. Conclusion: The
approach with PBSC in transplantation was safe and the engrafment
occurred in short time. Unfortunately, three patients developed platelet
transfusion refractoriness. The use of PBSC for treatment of relapse or
graft failure was unsuccessfully, because we observed severe pancytope-
nia and severe graft versus host disease. The use of PBSC for pts with
Epstein Barr infection after BMT is a good option. It is necessary to
obtain the minimal dose of CD34+ and CD3+ for achieve response in
patients with relapse.
PROLONGED DEFICIENCY OF IN VITRO SYSTHESIS OF IL-12 AND
TYPE 1 CYTOKINES IN RECIPIENTS OF ALLOGENEIC STEM CELL
TRANSPLANT (SCT).
M Grimley, S Lee, A Marton, A Filipovich. Children’s Hospital Medical Center,
Cincinnati, OH, USA
Many of the late complications following mismatched stem cell transplant
can be traced to the prolonged recovery of cell-mediated immunity. To
understand the mechanisms potentially underlying this extended immunode-
ﬁency, we have begun to quantitate the generation of regulatory cytokines by
mononuclear cells from transplant recipients collected at various time points
post SCT and activated in vitro. PBMC were stimulated in culture with
Staph Protein A (SAC) for IL-12 or Phtyohemagglutinin (PHA) for (-IFN,
IL-4, IL-10 and IL-2. Cytokine production was quantiﬁed by ELISA of cul-
ture supernatants.
TIMEDONOR 100 DAYS 6 MONTHS 1 YEAR POST NORMAL
TYPE POST SCT POST SCT SCT CONTROLS
Mean MSD 575 354 869 1761
-IFN
MUD 239 157 1052
Auto 2648 431 2326
Mean MSD 1390 1683 529 2391
IL-2
MUD 552 1013 367
Auto 1481 270 1636
Mean MSD 1.1 0.2 3.6 6
IL-12
MUD 1.1 1.1 0.8
Auto 0.3 * 11.0
MSD=Matched Sibling donor; MUD=Matched Unrelated Donor;
Auto=Autologous recipient. Mean IL-12, IL-2 and (-IFN production in
pg/ml. * -no data available.
Our data reveal decreased IL-12 production in all SCT recipients initially,
with normalization in MSD and Auto SCT patients by 12 months. In MUD
SCT patients, IL-12 production remains depressed beyond 1 year post SCT.
Overall, allogeneic recipients have low in vitro production of Type 1






TYPE 1 AND TYPE 2 T-CELLS IN THE STEM CELL GRAFT AND POST-
TRANSPLANT VIRAL INFECTION.
TG Gross, JC Lynch, JR Davis, SJ Pirruccello, EC Reed, MR Bishop,
ZS Pavletic, JO Armitage, A Kessinger, SR Tarantolo. University of
Nebraska Medical Center, Omaha, NE. Children’s Hospital Medical
Center, Cincinnati, OH
Previously, we showed that an increase in type 1 ((-IFN+) T-cells,
and a higher ratio of type 1 (T1) to type 2 (T2) (IL-4+) T-cells in
the stem cell graft correlates with developing acute GvHD. We
hypothesized that a lower T1/T2 ratio in the stem cell graft may
pedict patients (pts) at risk for post-transplant viral complications.
Fifteen pts received related, HLA-matched, G-CSF mobilized,
allogeneic blood stem cell grafts. All pts received the same prepara-
tive regimen, GvHD prophylaxis, and CMV prophylaxis, monitor-
ing and therapy. The content (% of cells) and dose (x109 cells/kg)
of T1 and T2 cells in the stem cell graft were determined using
intracellular cytokine staining and multiparametric FACS analysis.
Twelve pts were evaluable for viral complications up to day +100.
Four pts developed CMV infection, one pt died of CMV pneumo-
nia. One pt developed EBV associated post-transplant lymphopro-
liferative disease, and 1 pt died of a disseminated adenoviral infec-
tion. Median values for each group are reported, p>0.05 was
considered not signiﬁcant (NS).
%T1 DOSE T1 %T2 DOSE T2 T1/T2
CMV 1.9 0.3 0.2 0.1 5.5
No CMV 0.5 0.2 0.8 0.4 1.0
p=value NS NS NS NS 0.03
Viral Complication 1.5 0.2 0.3 0.1 3.9
No Viral Complication 0.5 0.2 0.8 0.4 1.0
p=value NS NS 0.05 0.05 NS
These results suggest that a relative increase in T2 cells and/or
decrease in T1 cells in the stem cell graft may identify patients at
lower risk of post-transplant viral complications.
TRANSPLANTATION OF PERIPHERAL BLOOD PROGENITOR CELLS
FROM UNRELATED DONORS.
H.Hägglund, E.Sparrelid, M.Remberger, B.Lönnqvist, P.Ljungam, J.Aschan,
G.Kumlien, P.Hentschke, S.Carlens, J.Mattsson, J.Winiarski, O.Ringdén. Allo-
geneic Stem Cell Transplant Unit and Depts. of Clinical Immunology, Infectious
Diseases, Hematology, Pediatrics and The Blood Bank, Huddinge Hospital, Sweden
Purpose. Transplantations of peripheral blood progenitor cells
(PBPC) from related donors are increasing rapidly. However, the expe-
rience using unrelated PBPC is limited. We here report single-center
results of unrelated PBPCT compared with unrelated BMT.
Methods. Sixteen patients with hematological diseases received
PBPC from unrelated donors. These patients were compared retro-
spectively with 16 recipients of unrelated BM and were matched for
diagnosis, disease stage, age, conditioning and GVHD prophylaxis. All
donors were HLA-A, -B and -DR compatible. The donors of PBPC
were treated with G-CSF, 10 (g/kg/day, for 4-5 days and follow-up of
the Swedish donors (n=11) are scheduled 3 months, 1 and 5 year after
donation.
Results. The PBPC graft contained a signiﬁcantly higher number of
MNC, CD34+ and CD3+ cells (p<0.01). The median follow-up time
was 16 (7-34) and 24 (7-41) months in the PBPC and BM groups,
respectively. All 32 patients had neutrophil engraftment. Time to
ANC>0.5x109/l was 6 days faster in the PBPC group compared to the
BM group (p=0.003). The cumulative incidence of acute GVHD grades
II-IV was 44% in the PBPC group and 32% in the BM group, respec-
tively (ns). The cumulative incidence of grades III acute GVHD was
13% in both groups. No patient experienced acute GVHD grade IV.
The cumulative incidence of chronic GVHD was 61% in both groups.
The 1-year probability of TRM was 25% and 43% (ns), 2-years proba-
bility of relapse was 24% and 35% (ns), and 2-years probability of
patient survival was 59% and 43% (ns), in the PBPC and BM groups,
respectively. In none of the Swedish donors were severe side effects of
the procedure reported.
Conclusion. This preliminary experience suggest that unrelated
PBPC is a safe procedure both for the donor and patient.
EX VIVO EXPANSION OF CANINE DENDRITIC CELLS.
H. Hägglund, G. Mathioudakis, B. Bruno, G. Georges, J. Gass, P. McSweeney, R. Storb
and R. Nash. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle
This is the ﬁrst report of ex vivo expansion of canine dendritic cells.
Material and method: CD34+ and CD34- canine bone marrow cells (105/ml)
were cultured in Iscoves medium with, GM-CSF and ﬂt3-ligand from day 0 and
TNF- ( from day 7. The cytokine concentrations used were GM-CSF 5, 50 and
500 ng/ml, ﬂt3-ligand 0.2 and 20 (g/ml, and, TNF-( 10, 100 and 250 ng/ml. Cell
count and ﬂow cytometry (FACS) were done on day 9 and a mixed lymphocyte
culture (MLC) was established to assess function.
Results: The cell number, “DC-like” phenotype or alloreactivity did not
increase with increased GM-CSF, ﬂt3 and TNF-( doses.
CD34+ CD34+ CD34+ CD34- CD34- CD34-
GM-CSF GM-CSF GM-CSF GM-CSF GM-CSF GM-CSF
5ng/ml 50ng/ml 500ng/ml 5ng/ml 50ng/ml 500ng/ml
Cellcount 360 350 150 70 50 40
(103/ml)
(340-425) (300-410) (100-290) (40-90) (30-60) (20-60)
Phenotype (%)
MHC II+/CD14- 44 n.d. 52 5 n.d. 2
(41-52) (44-59) (4-7) (2-2)
CD1c+/Cd11c+ 48 n.d. 46 14 n.d. 18
(39-52) (43-49) (2-21) (14-20)
MLC (CPM) GM-CSF 5NG/ML GM-CSF 50NG/ML GM-CSF 500NG/ML
CD34+ - derived vs URD2 6105 1703 6996
CD34- - derived vs URD 1972 919 1057
All numbers are median (range). 1The cultured cells were split on day 5. CD34+
-derived cells were irradiated cultured CD34+ cells (stimulators), CD34- -derived
cells were irradiated cultured CD34-cells (stimulators). 2URD; unrelated mononu-
clear donor cells (respondors), MLC; mixed lymphocyte culture, cpm; counts per
minute, n.d.: not done
The cultured CD34+ cells: 1) had a 5 fold expansion in total cell number, 2)
showed a morpholog consistent with a DC phenothype; MHC Class II+, CD1c+,
CD11c+, CD34- and CD14-, 3) and showed increased allostimulatory activity
compared to cultured CD34- cells.
Conclusion: GM 5ng/ml, ﬂt3 0.2(g/ml and TNF-( 10ng/ml is sufﬁcient for expan-
sion of “DC-like” cells from CD34+ cells. Future studies will determine if infusion of
DC will inﬂuence engraftment, GVHD and tolerance in a dog transplant model.
LYMPHOCYTE RECOVERY AFTER ALLOGENEIC PERIPHERAL BLOOD
TRANSPLANTATION (APBT) CORRELATES WITH THE SEVERITY OF
REGIMEN RELATED ORGAN DYSFUNCTION (OD).
WD Haire, ZS Pavletic, SR Tarantolo, BG Gordon, MR Bishop. Uni-
versity of Nebraska Medical Center, Omaha, NE
Delayed lymphocyte recovery after APBT is associated with
increased mortality (BMT 21:33, 1998). Neither the cause of this
delayed recovery nor the mechanism of death is understood. Death
in the early post-transplant period is generally due to the Multiple
Organ Dysfunction Syndrome (MODS), a syndrome felt to be
caused by abnormal immune and inﬂammatory responses to the
preparative regimen and other, less well deﬁned parameters (JAMA
274:1289, 1995). Because of the intimate involvement of lympho-
cytes and their products in the pathogenesis of MODS and their
correlation with APBT mortality, we analyzed the relationship of
lymphocyte recovery (day to recovery of 500 lymphocytes/cmm -
ALC500) to OD during APBT. Thirty nine APBT patients were
monitored daily for CNS dysfunction (drop of >4 points in the Fol-
stein mini-mental status exam), pulmonary dysfunction (O2 satura-
tion of <90% on 2 occasions >4 hours apart) and hepatic dysfunc-
tion (weight gain >5%, bilirubin >2 mg% and abdominal pain).
The severity of illness score (SIS) was calculated by totaling the
number of daily OD’s (0-3) through the entire hospitalization. The
ALC500 ranged from 9 to 75 days after beginning the preparative
regimen (median 15 days). Fourteen patients experienced at least
one OD during the transplant course. The first OD occurred
before day 14 in all patients (range 1-13). In these 14 patients the
SIS correlated with the ALC500 (R=0.665, p=0.01). Once OD had
occurred, patients with more severe MODS had greater delays in
lymphocyte recovery. When considering factors contributing to
delayed immune reconstitution after APBT, severity of regimen-
related MODS should be included. Conversely, the immune deﬁ-
ciencies associated with delayed immunologic reconstitution may
be pathogenetically related to prior MODS.
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OUTCOMES OF RELATED AND UNRELATED UMBILICAL CORD BLOOD
(UCB) TRANSPLANT: A SINGLE INSTITUTION EXPERIENCE.
PR Haut, M Olszewski, M Kletzel. Children’s Memorial Hospital,
Chicago IL
Between January 1995 and February 1998 24 unrelated and 2 related
UCB transplants were performed in patients (pts) with a median age of
6.8 years (range = 1.3-20.6). Diagnoses included hematologic malignan-
cy (n=17), myelodysplastic syndrome (n=2), marrow failure (n=4), and
immune deficiency (n=3). Median weight was 19.2 kg (range = 6.3-
69.4). HLA disparity included: 0 antigens (n=2), 1 antigen (n=9), 2 anti-
gens (n=11), 3 antigens (n=4, 2 related). Ablation for 21/26 pts was total
body irradiation (TBI)(150 cGy BID x 4 days), cyclophosphamide
(Cy)(60 mg/kg x 3 days) and Thiotepa (TT)(10 mg/kg) with etoposide
(VP-16)(1000 mg/m2 continuous infusion x 2 days) added in patients
with malignancy. Five patients received one of the following regimens:
TBI/VP-16/TT (n=1), Busulfan/VP-16/TT (n=1), TT/Cy, TBI (150
cGy BID x 2 days)/Cy (n=1), and no ablation (n=1), GVHD prophylaxis
consisted of continuous infusion cyclosporin, short course methotrex-
ate, and anti-thymocyte globulin. Median total nuclear cell, mononu-
clear cell and CD34+ cell dose infused was 8 x 108/kg, 0.4 x 108/kg, and
0.6 x 106/kg respectively. Median days to ANC > 500/(l was 26 (15-51)
and platelets > 20,000/(l was 41 (16-100). Twenty-two pts had engraft-
ment documented by VNTR, cytogenetics or HLA typing. Four pts
died prior to documented engraftment but only one death occurred
after the median time to engraftment for this group of pts. Fourteen pts
had documented infections. Two pts had grade 4 mucositis requiring
intubation. Eleven pts had grade 2 or less acute GVHD, 1 pt had grade
4 acute GVHD. Two patients developed chronic GVHD, one exten-
sive. The one hundred-day mortality was 35%. Overall survival is 40%
with a median follow-up of 766 days. Two of 10 patients with malig-
nancies have relapsed. The described ablative regimen and GVHD pro-
phylaxis for UCB transplantation resulted in acceptable rates of engraft-
ment and GVHD given the degree of HLA disparity in this group of
patients, however, the acute morbidity and mortality for the group was
high. Modiﬁcations in the conditioning are being evaluated to reduce
potential regimen-related toxicity.
CD34+ SELECTED BLOOD-DERIVED HLA-IDENTICAL ALLOGRAFTS
FOR HEMATOPOIETIC MALIGNANCY IN OLDER PATIENTS: LOW RISK
OF GVHD AND EARLY TRM.
TP Hughes, P Dyson, T Rawling, D Thorpe, C Rawling, N Horvath, G
Dart, P Bardy, LB To. Division of Haematology, Hanson Centre for
Cancer Research, IMVS, Adelaide, South Australia
Older patients receiving allografts have a high early transplant mor-
tality (TRM) with GVHD being a major cause. A pilot study was
undertaken in older patients (median age 51, range 41-60) with
hematopoietic malignancies and HLA-identical donors using Filgras-
tim-mobilised blood cells which were CD34+ selected with the Isolex
300i device. Conditioning therapy was TBI 1200 cGy and cyclophos-
phamide 120 mg/kg. GVHD prophylaxis was cyclosporin only.
Donors received Filgrastim 10 ug/kg daily (donors 1-9) or twice daily
(donors 10-18) and were leukapheresed daily from day 4 until they
achieved a target CD34+ cells dose of 5 million/kg recipient body
weight after selection. Eighteen patients are enrolled - 4 CML, 2
ALL, 4 AML, 1 MDS, 3 Myeloma and 4 NHL (7 in early stage and
11 in advanced stage disease). Three of the ﬁrst 9 donors and one of
the second 9 donors mobilised less than 3 million CD34+cells/kg and
unselected cells were also given; 2 of these patients died early of
GVHD (1 case) or multiorgan failure (1 case). The remaining 14
patients received a median of 5.4 million CD34+ cells/kg (range 3.2-
11.4) and 180,000 CD3+ cells/kg (3.5 log depletion). Neutrophils
recovered to 500/ul by day 14 (range 10-22) and platelets reached
50,000/ul by day 15 (range 11-70). Acute GVHD was grade 0-1 in
11/13 patients and grade 2-3 in 2 cases. Four patients with leukemia
who had only grade 0-1 GVHD were given 3 x 107 donor CD3+
cells/kg on day 60. One developed fatal grade 4 GVHD; 2 developed
extensive chronic GVHD. TRM at 6 months was 20% in patients
receiving only CD34+ selected cells and 33% for all patients. No
patient has relapsed (median FU 11 months). We conclude that
CD34+ selected blood allografts represent a promising approach in
older patients, which might reduce the risk of GVHD and TRM.
COMPARISON OF CD4+ CTL EFFECTOR FUNCTIONS THAT MEDIATE
SYNGENEIC GVL AGAINST DIFFERENT MYELOID LEUKEMIAS.
Michael Hsieh, Robert Townsend, and Robert Korngold
It is unclear whether and how GVL-mediating CD4+ T cells
mediate direct antileukemic cytotoxicity in vivo. We sought to
determine the role of perforin-, Fas ligand (FasL)-, and TNF-
dependent mechanisms in the development of CD4+ T cell-medi-
ated GVL activity against several myeloid leukemias.
These studies were performed using MMB1.10, MMB2.18, and
MMB3.19; which are myc-transformed, mouse myeloid leukemias
of C57B1/6 (B6) origin. Flow cytometric analysis revealed that all
three tumors express high levels of cell surface Fas. RT-PCR
detected mRNA for TNF receptor (TNF-R) type I and II in all
three leukemias. Despite expression of TNF-R, none of the tumors
were sensitive to TNF-mediated cytotoxicity as determined by
MTT assays. For GVL mortality assays, B6 mice were lethally irra-
diated followed by challenge with tumor, and administration of
either bone marrow alone or bone marrow in combination with
tumor-presensitized CD4+ T cells. Use of wild type (w.t.), per-
forin-deﬁcient (pfp0), or FasL-deﬁcient (gld) B6 donors revealed
that CD4+ CTL rely equally on perforin and FasL in order to
exert GVL activity against MMB1.10. Use of w.t., pfp0, and gld
donors in the MMB3.19 GVL model demonstrated that CD4+
CTL rely primarily on FasL and secondarily on perforin. An indi-
rect role for NK cells in both GVL models was excluded through
in vivo depletion of NK cells.
The differences in effector mechanisms utilized by CD4+ CTL
against various leukemias does not appear due to intrinsic sensitivi-
ty of the tumors to perforin- versus FasL-mediated cytotoxicity;
CD8+ T cells from pfp0 donors are equally as poor at mediating
GVL against MMB3.19 as CD4+ T cells from gld donors. We pos-
tulate that myeloid leukemias express tumor antigens that skew
CD4+ CTL responses towards certain effector mechanisms over
others.
G-CSF PRIMED BONE MARROW IMPROVES DELAYED ENGRAFTMENT
PRODUCED BY MTX CONTAINING GVHD PROPHYLAXIS REGIMENS.
L. Isola, E. Scigliano, D. Skerrett and S. Frutchtman. BMT Service, Division of
Hematology, Department of Medicine, Mount Sinai Medical Center, NY, NY, USA
Purpose of the Study: Administration of G-CSF leads to increased number of
progenitors in harvested bone marrow. We previously demonstrated that G-CSF
primed bone marrow (pBM) is a suitable source of stem cells for allogeneic trans-
plantation1. The combination of methotrexate (MTX) and cyclosporin A (CSA) or
tacrolimus (FK) is commonly used for GvHD prophylaxis after allogeneic trans-
plantation. Prednisone and CSA or FK regimens results in more rapid hematopoi-
etic reconstitution but steroids have undesirable side effects. We examined
whether the use of pBM can offset the delayed engraftment seen with MTX con-
taining GvHD prophylaxis. Methods: Seventeen patients received pBM from
matched sibling donors who received G-CSF at 10 mcg/kg/day for 2-4 days prior
to harvesting. Conditioning was TBI/CY, Bu/CY or TLI/CY/ATG. All grafts
contained 3.5-4x108 MNC/kg. Ten out of 17 patients received MTX as part of
their GvHD prophylaxis. IBMTR deﬁnitions of ANC>500 and plts>20,000 were
used. Historical controls for engraftment were 112 consecutive pts. who received
allogeneic BMT at our institution with unstimulated BM (BM). For length of stay,
controls were the subset transplanted during 1996. Results: Neutrophil and
platelet engraftment occurred more rapidly in both groups of patients receiving
pBM as compared to controls and this shortened hospitalization (see table). Peri-
transplant mortality was 18% (3/17). Fourteen patients remain alive on day 57-
1014 post-BMT. One patient in the pBM group who received CSA/PRD has
extensive chronic GvHD. One who received MTX/CSA had an isolated CNS
leukemic relapse and is now in CR.
Graft / MTX ANC>500* ANC>1,000* Plt>20,000* Hospital stay*
UBM / yes 24 ( 12 26 ( 13 26 ( 19 46 ( 15
PBM / yes 18 ( 3 21 ( 6 21 ( 5 34 ( 8
PBM / no 14 ( 4 17 ( 3 20 ( 5 36 ( 10
*Mean ( SD
Conclusion: the use of primed bone marrow allografts resulted in more rapid
engraftment and shorter hospitalization in this group of patients. Bone marrow prim-
ing can partially offset the delay in neutrophil and platelet recovery seen with the use
of MTX containing GvHD prophylaxis. G-CSF pBM transplants didn’t result in
higher than expected GvHD, disease relapse and/or peritransplant mortality.
Isola, L.M., Scigliano, E., Skerrett, D., Shank, B., Ross, V, Najfeld, V., Frucht-





PHENOTYPE AND FUNCTION OF GRAFT-VS-TUMOR CONFERRING
CELLS IN A MOUSE LYMPHOMA MODEL.
M Ito and JA Shizuru Stanford University Medical Center, Div. of Bone Marrow
Transplantation, Stanford, CA
In prior studies we showed in a mouse B cell lymphoma model, BCL1 that trans-
plantation of highly purified MHC-mismatched hematopoietic stem cells
(HSCs:Thy-1 loLin-/loSca-1+) results in 100% tumor relapse whereas transplanta-
tion of whole BM confers signiﬁcant GVT. Here we used the BCL1 model to
study the phenotype and function of cells with GVT activity, and to study if
MHC-matched BM can confer similar tumor protection. For the MHC-mis-
matched studies recipient mice were BALB/c (H-2d, Thy 1.2) and donors were
C57BL/Ka(BA:H-2b, Thy1.1). Recipients were inoculated with 103 BLC1 cells 1
wk prior to receiving lethal irradiation (XRT) and rescue with either whole BA
BM, BA HSCs only, or BA HSCs plus candidate GVT conferring cells puriﬁed
from BA BM (sorted CD3+, CD4+, CD8+, Mac1+, B220+ or NK1.1+ cells). No
tumor protection was noted in mice transplanted with BA HSCs only (n=15); BA
HSCs +Mac1+ cells (n=5), +CD4+ cells (n=8), +B220+ cells (n=5), or +NK1.1+ cells
(n=10). In contrast, signiﬁcant protection without GVHD was noted in mice trans-
planted with BA HSCs+CD3+ BM cells (60%, n=5), +CD8+BM cells (88%, n=8),
or control BA BM (50%). CD3+ and CD8+BA spleen cells were also protective,
however, CD3+ spleen cells caused GVHD. To study the mechanism of the GVT
effect, BALB/c received BCL1 1 wk prior to receiving XRT and rescue with BM
from immune defective knockout (K.O.) mice (perforin, IL-2, IFN-() or Fas-ligand
defective mice. All donors were of the C57BL/6 background. All perforin
K.O.(n=10) and Fas-ligand defective (n=10) BM transplanted mice died of tumor
within 10 wks post-transplant. 100% of IFN-( K.O.(n=7) BM transplanted mice
were tumor free but died within 10 wks post transplant, and IL-2 K.O. BM trans-
planted mice (n=15) died of a mixture of engraftment failure and tumor. To test if
MHC-matched BM has measurable GVT activity, BCL1 inoculated BALB/c (H-
2d, CD45.2) were transplanted with HSCs or BM from B10.HZ(H-2d, CD45.1). 1
wk after inoculation the mice were irradiated and rescued with B10.HZ HSCs or
BM. All HSC(n=10) and BM(n=10) transplanted mice died of tumor within 5-6
wks post-transplantation. Addition of splenic B10.HZ CD8+cells resulted in signif-
icant GVT without GVHD, and B10.HZ CD3+cells conferred GVT although at a
reduced level compared with CD8+cells. These studies suggest that in this model
of lymphoma relapse CD8+cells confer signiﬁcant GVT without causing GVHD
in both MHC-mismatched and MHC-matched strain combinations, and that
tumor protection is dependent upon intact granule mediated cytolytic and Fas
pathways. IL-2 appears to contribute weakly to tumor protection while IFN-(‘s
role appears to be minimal.
IPOTENTIAL FOR CLINICAL APPLICATION OF THE T-CELL BYPROD-
UCT FROM ELUTRIATION T-CELL DEPLETION AS PROPHYLACTIC
DONOR LEUKOCYTE INFUSION.
W.E. Janssen, R.C. Smilee*, M.J. Farmelo*, K.K. Fields, S.C. Goldstein. Blood and Marrow
Transplant Program, H. Lee Mofﬁtt Cancer Center, University of South Florida, Tampa, FL.
T-cell depletion (TCD) from marrow allografts has been shown to reduce the
incidence and severity of graft versus host disease (GvHD), albeit with increased
risk for graft failure and/or relapse of disease. The risk of graft failure appears to
diminish with minimal T-cell content in the graft and relapsed disease has been
effectively treated in some cases with infusion of 106-108 donor T-cells/kg. The lat-
ter requires additional cell collection from the donor. For patients at high risk for
severe acute GvHD, we have performed TCD using counterﬂow centrifugal elutri-
ation (CCE) and CD34 positive selection. This approach has the unique advantage
of retaining functional depleted T-cells for insuring minimum T-cell content in the
graft and for subsequent donor leukocyte infusion (DLI) for relapse and/or prophy-
laxis. Following CCE, the small cell fractions are pooled and processed using the
CeprateTM CD34 cell selection system. The large cell fraction from CCE and the
CD34+ cell fraction from CD34sel are given to the patient. Additionally, sufﬁcient
cells from the T-cell rich CD34 negative cell fraction from CD34 selection are
infused to achieve a ﬁnal target CD3+ cell dose of 0.5x106/kg. The unused, T-cell
rich, CD34neg fractions (T-cell byproducts) are cryopreserved for future use. Data
from 12 patients undergoing TCD is summarized:
MEDIAN(RANGE) MNC X106/KG CD34+ X106/KG CD3+ X106/KG
Start Marrow 451 (289-964) 4.6 (0.9-10.4) 51 (17-65)
Tot. Infused 43 (6.0-118) 0.8 (0.3-3.1) 0.8 (0.4-5.1)
The median days to achieve an ANC>500 for these patients was 13.5, exclusive
of two graft failures. To determine the potential suitability of the frozen T-cell
byproducts for DLI, they were analyzed, revealing:
MNC X106/KG CD34+ X106/KG CD3+ X106/KG CD4/CD8 RATIO
34.4 (7.3-98.3) 0.3 (0.06-1.4) 17.4 (2.9-27.4) 1.2 (0.3-3.8)
We have also observed NK cells and both macrophage and dendritic lineage
antigen presenting cells in the T-cell byproducts. These data compare with DLI
products that may be obtained from donor leukopheresis. Our results suggest that
the CCE + CD34 selection yields a functional graft and also a T-cell byproduct
which may be used clinically for DLI. This may be particularly advantageous in
unrelated marrow transplant, wherein access to donors subsequent to original har-
vesting and transplant is not assured.
RAFT VERSUS HOST DISEASE (GVHD) WITH GRAFT VERSUS MYELO-
MA EFFECT POST AUTOLOGOUS TRANSPLANT.
N. Janakiraman, C. Kasten-Sportès, S. Burt, I. Vial, J. Rogers, V. Ford-
Cattaneo, V. Pindolia, Henry Ford Health System, Detroit, Michigan
The graft versus tumor effect of allogeneic bone marrow trans-
plantation is being increasingly recognized, prompting attempts at
reducing cytotoxic therapy and adding donor lymphocyte infusions
(DLI). There are a few reports of beneﬁts from DLI in patients
with relapsed multiple myeloma showing graft versus myeloma
effect. In a disease associated with high mortality from allogeneic
transplantation, here is an opportunity to increase the therapeutic
index. We report a patient with relapsed multiple myeloma who
developed GVHD post autologous stem cell transplant and
achieved a complete remission.
JM was a 61 year old male when he was diagnosed to have Stage
IIA, IgA lambda, multiple myeloma. Refractory to VAD X 8 and
Melphalan/prednisone X 8, in 5/93 he received Melphalan 140
mg/m2 and fractionated TBI 960 cGy, followed by autologous
Cytoxan-mobilized stem cells. He achieved a very good partial
remission, with reduction in IgA levels from 4910 mg/dl to 600
mg/dl; however, there was a persistent monoclonal peak. Neu-
pogen-mobilized stem cells were harvested during this remission
and stored.
Patient relapsed in early 1998 and received Melphalan 200
mg/m2 followed by 7.21 X 108 mononuclear cells/kg (CD34, 1.01
X 106/kg). About 4 weeks after infusion patient developed general-
ized erythematous rash consistent with GVHD of the skin. Skin
biopsy at 3 months conﬁrmed grade 3 GVHD. Interestingly, his
monoclonal protein could not be detected at that time, even by
immunoelectrophoresis. He was treated with steroids, with
improvement of the skin rash; however, he had poor engraftment
and died four months later of sepsis.
This case suggests the therapeutic beneﬁt of GVHD in myeloma,
which can be realized both in the autologous and allogeneic setting.
GVHD INDUCED BY DOUBLE CYTOTOXICALLY DEFECTIVE DONOR T
CELLS: OTHER EFFECTOR PATHWAYS CAN INDUCE GVHD WITH
NOTABLY REDUCED EFFICIENCY.
Z. Jiang, N. Altman, M. Jones, E. Podack and R.B. Levy. Dept. of Microbiology
and Immunology. Univ of Miami School of Medicine, Miami, FL 33101
To investigate effector mechanisms involved in the development and
pathogenesis of graft-versus-host disease (GVHD), allogeneic bone
marrow transplants (BMT) were performed with cytotoxically defective
donor T cells. T cells from C57BL/6(H-2b) Perforin/FasL double-deﬁ-
cient mice (B6-CDD) together with C57BL/6 Ly5a congenic bone
marrow were transplanted into MHC class I/II mismatched lethally
irradiated BALB/C (H-2b) recipients. Compared to the recipients of
0.5x106 wild type B6 T cells, BALB/C mice transplanted with 10X
higher number (5x106) of B6-CDD T cells exhibited similar clinical
signs of GVHD, including body weight loss, diarrhea, skin lesions and
hair loss. Mice receiving 0.5x106 B6-CDD T cells exhibited a delayed
and milder disease process. The number of spleen cells in long term
surviving recipients of B6-CDD T cells, while initially higher vs spleen
numbers B6 T cell transplanted mice, began to decrease within two
weeks and diminished to the same number as in the recipients of syn-
geneic T cells. No evidence of lymphoproliferation or pancreatic and
uterine inﬁltration by lymphocytes and monocytes/macrophage charac-
teristic of CDD syndrome were identiﬁed in any BMT recipients. Mor-
tality was observed in 60% and 40% of 5x106 and 0.5  106 B6-CDD (
BALB/C recipients, respectively. Notably, 4 months post-BMT, analy-
sis of recipient spleen and lymph node cells in B6-CDD T cell trans-
planted mice revealed that >95% of cells were Kb+Ly5a+, indicating
they were derived from the donor bone marrow Innoculum. PCR and
phenotypic analysis demonstrated some CDD cells still persisted (~3%)
in these spleens of the recipients. In total, the observations demonstrat-
ed: 1) Perforin/FasL double deﬁcient T cells were capable of causing
GVHD, however, comparable kinetics required 10X greater T cell
numbers, and 2) allogeneic bone marrow was able to engraft when
transplanted together with B6-CDD donor T cells. Notably, CDD T
cells caused severe skin damage and hair loss, pathogenic processes not
previously observed following BMT with FasL defective gld T cells.
Further studies to understand these differences are being performed.
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CHARACTERIZING THE EPITHELIAL INFILTRATION OF TCR V( FAMI-
LIES IN A CD4+ T CELL MEDIATED MURINE MODEL OF ACUTE
GRAFT-VERSUS-HOST DISEASE. 
Stephen C. Jones, Thea M. Friedman, Debbie Statton, Mark Berger,
George Murphy and Robert Korngold Kimmel Cancer Center, Thomas
Jefferson University, Philadelphia, PA
C57BL/6By (B6) CD4+ T cells respond to minor histocompata-
bility antigen (miHA) disparities in the BALB.B mouse. Aside from
providing help for a lethal alloreactive CD8+ T cell response, they
are alone capable of causing death in this murine model of graft-
versus-host disease (GVHD). This research focuses on the latter of
the two responses and is principally concerned with molecularly
characterizing the responding B6 CD4+ T cell population and cor-
relating this with expanding T cells identiﬁed directly at a GVHD
target tissue site. CDR3 size spectratyping, a PCR based technique,
was used to identify biases in the B6 CD4+ TCR V( repertoire once
transplanted into lethally irradiated BALB.B recipients. Skewing of
the CDR3 size distribution for a particular V( is suggestive of clon-
al or oligoclonal minor antigen driven expansion of that V(.
Immunohistochemical analysis on epithelial tissue, a classical
GVHD target organ, was performed with a panel of monoclonal
antibodies speciﬁc for a number of V( families. We noted a larger
inﬁltration in the BALB.B lingual epithelial tissue of V(+ cell popu-
lations which were skewed in the CDR3 size spectratype analysis
compared to CD4+ T cells expressing a V( that did not show a
biased CDR3 size representation. Furthermore, we directly
observed a representative skewed V( expressing T cell population
involved in a classical acute GVHD lymphocyte reaction pattern.
These results demonstrate that the expansion of V( families as
identiﬁed by spectratype analysis correlates with the pathogenesis
of GVHD.
PHARMACOKINETICS OF ORAL AND I.V. MYCOPHENOLAT MOFETIL
(MMF) IN PTS AT HIGH RISK FOR GVHD.
W Willenbacher1, V Armstrong2, AM Hartert1, M Oellerich2, M Ship-
kowa2, N Basara1, IW Blau1, AA Fauser1, MG Kiehl1. 1Center for
BMT & Hematology, Idar-Oberstein, 2Dep. of Clinical Chemistry,
Georg-August University, Göttingen; Germany
GvHD is a leading cause of morbidity and mortality post-BMT,
especially in the setting of MUD and/or HLA-mismatched TX.
One strategy to address this issue is the use of alternative immuno-
suppressive agents such as MMF. As shown previously1 pre-dose
blood levels of the main metabolite MPA are low in the early post-
BMT phase if MMF is given p.o., (although a therapeutic range in
the BMT setting has yet to be deﬁned). A prospective study of the
pharmacokinetics of a 2 x 1 g/d i.v. MMF schedule was instituted in
pts. at high risk for GvHD (HLA mismatched VUD BMT) given
from day + 10 onwards in addition to a standard immunosuppres-
sive regime. Measurements of MPA were performed by EMIT and
HPLC assays2. In contrast to the oral application of MMF higher
blood levels of MPA were achieved with i.v. MMF; although the
AUC0-12h was still well below values in organ TX (Media 20 mg x
h/L vs. 40 mg x h/L). No second peak after 6h as in p.o. adminis-
tration was observed. Clinical response was documented in several
pts. switching from p.o. to i.v. MMF. Additional data on pharma-
cokinetics and clinical effectiveness of i.v. MMF will be presented.
References:
1 Hartert et al., BMT 1998 (submitted),
2 Schütz & Shipkowa, Trans Proc 30: 1185, 1998
TREATMENT OF REFRACTORY ACUTE AND CHRONIC GRAFT VERSUS
HOST DISEASE (GVHD) WITH ANTI TAC ANTIBODY (ZENAPAXR):
EFFECTS ON ACTIVATED T CELLS AND IN VITRO IMMUNE FUNCTIONS. 
N Kapoor, K Weinberg, M Smorswensky, G Crooks, D Kohn, R Parkman, Chil-
drens Hospital Los Angeles, Los Angeles, CA
Nine patients between the ages of 3.5 and 17 years (8 recipients of unrelat-
ed bone marrow and 1 recipient of maternal bone marrow) developed graft
versus host disease which progressed in spite of standard GVHD therapy.
Four patients had refractory acute GVHD, and ﬁve others had refractory
chronic GVHD. Three patients with acute GVHD had only skin involve-
ment, and one had both skin and gut involvement. One patient with chronic
GVHD had only liver involvement, and 4 patients had both skin and gut
involvement. All the patients had previously received standard graft versus
host disease prophylaxis and subsequently additional therapy with
cyclosporine or FK 506, steroids, antithymocyte globulin, mycophenolate
mofetil and/or PUVA. All the patients had failed to achieve clinical resolu-
tion or improvement of their GVHD.
All patients were treated with Zenapax while receiving their other current
immunosuppressive therapy. All the patients received the drug at a dose of 1
mg/kg/dose given on Days 1 and 4 and then weekly doses for a total of ﬁve
doses in six patients and six doses in three patients. All patients had immuno-
logical evaluations including peripheral blood immunophenotyping and T
lymphocyte blastogenic responses to mitogens and antigens. Eight of nine
patients had either complete or partial resolution of their GVHD processes.
One patient died four weeks following the completion of treatment due to
overwhelming pulmonary infection due to multiple bacterial, fungal and viral
microorganisms.
Prior to the treatment with anti-Tac antibody, all the patients had a high
the percentage of CD25+, CD26+ and DR+ T lymphocytes. Following treat-
ment there was a marked decrease in CD25+ cells without signiﬁcant alter-
ation in percentage of CD26+ and DR+ cells. However there was a complete
abrogation of T lymphocyte blastogenic responses to both mitogens and
antigens. The exact time when these blastogenic responses will recover fol-
lowing the completion of anti-Tac antibody therapy and what will be the
effect of the recovery of immunological function on the patients’ clinical
graft versus host disease status is under active study.
DIFFERENTIAL INFECTION OF DIVIDING LYMPHOCYTES BY RETROVI-
RAL VECTORS ENCODING AN IMMUNOLOGICALLY SELECTABLE
MARKER PERMITS PREFERENTIAL ENRICHMENT OF VIRUS-SPECIFIC T
CELLS EARLY AFTER IN VITRO SENSITIZATION.
G. Koehne, H.F. Gallardo, M. Sadelain and R. J. O’Reilly. Bone Marrow
Transplantation Service, Depts. of Pediatrics and Human Genetics. Memorial
Sloan-Kettering Cancer Center, New York, NY
Retroviral vectors are known to selectively transduce proliferating cells.
We wished to test whether this property of retroviruses could be exploited to
select for EBV-virus reactive T cells early in the course of in vitro sensitiza-
tion of PBMC. Replicate cultures of peripheral blood mononuclear cells
were stimulated in vitro with mitogens or with 6000cGy irradiated autolo-
gous EBV transformed B cells. At varying times post stimulation, one of the
replicates was infected with the retroviral vector. For this purpose, we used a
MLV-based dicistronic vector, termed NIT, encoding a mutant NGFR and
herpes simplex virus-thymidine kinase (hsv-tk). Test cultures were trans-
duced during maximum initial proliferation (day 4 and day 7 for PHA and
EBV transformed cells, respectively, as assessed by 3H thymidine incorpora-
tion), at a MOI 1-2 for 24 hours on ﬁbronectin fragments. Under these con-
ditions, we regularly achieved transduction of 20-40% of the CD3+-lympho-
cytes. Sorting by two-color FACS resulted in collection of >98% puriﬁed
NIT+ cells and a separate NIT- fraction. In 51Cr release assays, NIT+ T cells
sensitized to autologous BLCL showed 70% speciﬁc lysis of the autologous
BLCL, as opposed to 20% by NIT- T cells and 30% by unselected, non-
transduced control cells at a ratio of 20:1. Lysis of allogeneic BLCL and
K562 targets was below 5% in the positive fraction. Limiting dilution analy-
ses showed an autologous EBV-BLCL speciﬁc T cell frequency of 1/5,778 in
the NIT+ cell population, a frequency of 1/202,003 in the NIT- fraction and
a frequency of 1/230,345 in the unmodiﬁed fraction, when the autologous
BLCL were used for stimulation. The frequency against an allogeneic BLCL
was <1/500,000 in the three cell fractions of this donor. Identically prepared
T cells from another donor showed, in LDA, a frequency of 1/10,265 against
autologous BLCL and 1/14,371 against the allogeneic BLCL in the unmodi-
fied T cells. In contrast, the NIT+ cells showed a frequency of 1/5,582
against autologous and 1/104,604 against the allogeneic BLCL. Transfer of a
vector encoding an immunologically selectable marker into T lymphocytes
early after sensitization permits multifold enrichment of EBV-specific T
cells, while depleting of allo-reactive T lymphocytes at the same time. Thus,
our genetic approach permits rapid selection and propagation of virus-specif-





B CELL POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER
GENETICS: RECURRENT ABNORMALITIES DEFINED BY MOLECULAR
CYTOGENETICS OF DNA IN T CELL DEPLETED BMT.
L.J. Krueger1, M. Ladanyi2, D.A.Filippa2, R.J.O’Reilly3 and S.P. Dunn1 St.
Christopher’s Hospital for Children1. Philadelphia, PA and Memorial Sloan-Ketter-
ing Cancer Center2,3, New York, NY
B cell posttransplant lymphoproliferative disorders (BPLDs) are complica-
tions in bone marrow transplantation. They range from benign hyperplasia
to frank lymphoma. Cytogenetic analysis of BPLDs is limited by the quali-
ty/quantity of the material, viability, mitotic activity, purity, heterogeneity
between specimens, sensitivity and other related technical issues. While
genetic analysis remains the keystone for the subclassiﬁcation of the BPLD,
limited progress in deﬁning the genetic pathways has occurred. Comparative
genomic hybridization (CGH), a global process deﬁning quantitative genetic
changes, was applied to a series of BPLD in BMT (n=16 pts). CGH identi-
ﬁes candidate areas of the genome facilitating the isolation of speciﬁc candi-
date genes.
16 BMT pts diagnosed with BPLD had an average age of 32 yrs (range 10
to 53 yrs) and a mean time to development of BPLD of 4 months (range 3-8
months). The BPLD biopsies were obtained from various tissues mostly
showing diffuse large cell lymphoma. 93% of the specimens evaluated were
positive for EBV; almost all showing EBV clonality. CMYC rearrangement
was absent by Southern blotting (0/12). In a subset (n=9), CGH deﬁned 22
subchromosomal or chromosomal gains (approximately 3 gains per patient)
with 2 losses of the X chromosome. Five regions were recurrent including:
1p, 16p, 17, 19q and 21. The gain of chromosomal subregion 1p34.2p36 in
these BPLD pts. has also been described as a marker for endemic, but not
sporadic Burkitt’s lymphoma (another EBV-associated lymphoma). In the
CGH cases, the IGH rearrangement analysis conﬁrmed the clonal nature of
the biopsy and the donor origin was conﬁrmed by donor-host polymorphism
analysis. CGH provides a global technique for deﬁning genetic lesions in the
initiation and progression of BPLDs. CGH analyses in BPLDs may show
genetic overlaps, improve discrimination between gene paths found in EBV-
associated lymphomas, deﬁne new genetic lesions and reﬁne the molecular
analysis of lymphomagenesis in BPLDs.
SINGLE LARGE VOLUME LEUKAPHERESES (LVL) AFTER 6 G/M2 OF
CYCLOPHOSPHAMIDE (CFF) ALLOW THE COLLECTION OF LARGE
HAEMATOPOIETIC GRAFTS FOR AUTOLOGOUS TRANSPLANTATION IN
MYELOMA.
F Leal-da-Costa, JL Passos-Coelho, A. Machado, N Miranda, MRG Silva, P.
Lúcio, A. Parreira. Hematology, Portuguese Institute of Oncology, Lisbon, Portugal
Large PBPC collections potentially ensure faster haematopoietic
recoveries and reduced complications and may allow safe ex vivo
manipulations and/or double transplants. Single LVL are cheaper and
more convenient for patients (pts) and for the transplant team allowing
for resources optimization. Since 1995 we have been collecting PBPC
with LVL after CFF (6g/m2) in multiple myeloma pts candidates for
autologous haematopoietic transplantation. Twenty one pts, median
age 48(33-67) y.o., received CFF on day 1 and ﬁlgrastim 10(7.8-12)
µg/kg/day starting on day 5. When mobilized 15 pts had less than one
year after diagnosis and 9 had only one line of previous anti-myeloma
treatment. One patient with pneumothorax, hemorrhagic cystitis and
neutropenic fever was not discharged after high-dose CFF and 10/20
pts were readmitted because of neutropenic fever. In only 1 pt, with
Rhodotorula rubra sepsis, was the harvest cancelled. There was no
treatment related mortality. LVL were performed, as previously
described(1), on day 14(13-18), when peripheral blood leucocyte count
was 32(1.48-72.9) X 109 /L, platelet count was 81(39-150) X 109 /L and
CD34+ count was 94(4-721) X 106 /L. With an average of 9.7(2.3 sd)
blood volumes collected in 304 (59 sd) min, at a ﬂow rate of 142(15 sd)
ml/min, 8.6(6.41-13.76) X 108 nucleated cells /Kg, and 10(0.06-55.5) X
106 CD34+ cells/kg were collected. Fourteen pts had > 5 X 106 /
CD34+ cells /Kg collected in a ﬁrst single procedure. Three pts had a
second mobilization with G-CSF and 1 pt had bone marrow harvested.
So far, 27 transplantations were performed in 19 pts. In conclusion,
PBPC collection with single LVL after mobilization with high dose
CFF and G-CSF is an effective way to collect large PBPC grafts.
(1) J.L. Passos-Coelho et al, Journal of Hematotherapy 1997;6:465-474.
PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE (GVHD) WITH
CYCLOSPORINE-PREDNISONE (CSP-PRED) IS ASSOCIATED WITH AN
INCREASED RISK OF CHRONIC GVHD (cGVHD).
K.R.Shaji Kumar*, M. Litzow, M. Chen, D. Gastineau, M. Gertz, D. Inwards,
M. Lacy, A. Tefferi, Mayo Clinic, Rochester, MN
We retrospectively reviewed the charts of 271 consecutive allogeneic relat-
ed blood and marrow transplants (BMT) performed at our institution
between 1982 and 1997 to determine the effect of two different GVHD pro-
phylactic regimens, cyclosporine-short course methotrexate (CSP-MTX)
and cyclosporine-prednisone (CSP-PRED), on the incidence of cGVHD.
CSP-MTX or CSP-PRED were used in 198 (73%) patients (pts) whereas
other regimens were used in the remaining 73 pts. Patients surviving <60
days post-BMT (n=30) were censored from the analysis for incidence of
cGVHD leaving 120 pts (71%) in the CSP-MTX group and 48 (29%) in the
CSP-PRED group. CSP-PRED was used in pts transplanted more recently
because of concerns of an increased risk of veno-occlusive disease of the liver
in pts receiving CSP-MTX. Marrow was the source of stem cells in virtually
all pts. The two groups did not differ signiﬁcantly with respect to age, sex,
HLA match (5/6 vs. 6/6), stem cell source, diagnosis, or conditioning regi-
men. Chronic GVHD occurred more commonly in the CSP-PRED group
(75%) than in the CSP-MTX group (43%) (p=0.0002). Among the 88 pts
(52%) who developed cGVHD, 56(64%) had extensive cGVHD and
32(36%) had limited cGVHD. The incidence of extensive cGVHD was
higher in the CSP-PRED group (52%) compared with the CSP-MTX
group (26%) (p=0.001). Clinical manifestations of cGVHD were similar in
both groups. The higher incidence of extensive cGVHD in the CSP-PRED
group contributed to increased late mortality in this group, but the overall
survival (n=198) did not differ signiﬁcantly between the CSP-MTX (n=145)
and the CSP-PRED (n=53) group. We conclude that the choice of prophy-
lactic regimen for acute GVHD can impact the incidence of cGVHD and
needs to be considered when comparing the incidence of cGVHD in studies
analyzing transplants from different stem cell sources.
DOUBLE CYTOTOXIC DEFICIENT MICE PRIMED TO DONOR ANTIGENS
CAN REJECT BONE MARROW ALLOGRAFTS.
R.B. Levy, M. Mammolenti, E. Podack and M. Jones. Dept. of Microbiology
and Immunology. University of Miami School of Medicine. Miami, FL 33101
The rejection of marrow allografts can frequently occur in recipients of
T cell depleted inoculum or in individuals who have been previously
exposed to donor antigens. To examine the involvement of the two
major cytotoxic pathways i.e., perforin dependent and FasL- dependent
killing utilized by lymphoid cells in a marrow rejection model, we
examined allografts transplanted into cytotoxic double deﬁcient (CDD)
recipients. Five week old B6-CDD and cytotoxic normal B6 (H-2b)
mice were primed against non-MHC allogeneic antigens by inoculation
of C3H.SW (H-2b) spleen, thymocytes and lymph node cells. Two
weeks later, primed and unprimed (control) recipients were irradiated
(9.0Gy TBI) and transplanted with T cell depleted marrow from
C3H.SW or B6 (syngeneic) donors. Resistance was assessed by assaying
spleen cells five days post-BMT for CFU-GM-CSF and CFU-IL-3
activity. Unprimed B6-CDD and unprimed normal B6 recipients con-
tained high numbers of CFU’s following transplant with 2x106 syn-
geneic B6 marrow. Unprimed B6-CDD recipients transplanted with
2x106 allogeneic C3H.SW marrow contained >150 and 120 CFU/cul-
ture GM-CSF and IL-3 respectively. B6-CDD primed and B6 primed
mice also demonstrated CFU activity after BMT with syngeneic B6
marrow. However, primed B6-CDD recipients contained marginally
detectable (<15 and <12) CFU-GM-CSF or CFU-IL-3 respectively
after transplant with 2x106 C3H.SW TCD marrow. Transplant with
4x106 C3H.SW TCD marrow also failed to result in signiﬁcant CFU
activity (<10 CFU/culture) indicating strong resistance in the B6-CDD
recipients. These results were indistinguishable from those which have
been obtained after identical BMT into primed B6 recipients. The pre-
sent results indicate that recipients simultaneously unable to mediate
perforin and FasL dependent cytotoxicity can effectively generate resis-
tance against progenitor cell engraftment. We conclude that a non-per-
forin and non-FasL dependent effector mechanism(s) can effect antigen
speciﬁc marrow resistance in this model. Experiments are underway to
examine for involvement of other death receptor/ligands and cytokines
in this model system.
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IN VITRO GENERATION OF CMV AND EBV SPECIFIC CYTOTOXIC T-
LYMPHOCYTE CULTURES.
Q. Sun, R. Burton, L.J. Dai, K. Pollok and K. Lucas; Bone Marrow Transplanta-
tion Program, University of Alabama at Birmingham
Epstein Barr virus (EBV) and cytomegalovirus (CMV) infections are a
serious cause of morbidity in patients receiving T cell depleted stem cell
transplants. Since cytotoxic T-lymphocytes (CTL) play a critical role in
controlling viral infections, the infusion of in vitro expanded, virus-spe-
ciﬁc CTL has been actively explored in therapeutic and prophylactic
regimens for EBV and CMV infections. We attempted to generate
EBV and CMV specific CTL cultures simultaneously using EBV-
immortalized B lymphoblastoid cell lines (BLCL) as stimulators. BLCL
and skin ﬁbroblasts (SF) were transduced with a recombinant retrovirus
that encoded the immunodominant CMV protein pp65 and a neomycin
selectable marker. BLCL transduced with pp65 (pp65-BLCL) and skin
ﬁbroblasts (pp65-SF) stained positive for pp65 using immunoperoxidase
staining and were positive by Western blot analysis. The pp65-express-
ing cells were co-cultivated with autologous peripheral blood mononu-
clear cells, and were tested for speciﬁc cytotoxicity against CMV and
EBV in chromium release assays. The pp65-BLCL primed CTL cul-
tures displayed speciﬁc cytotoxicity against pp65-expressing SF, pp65-
BLCL, and CMV infected SF. When non-transduced BLCL and
BLCL transduced with the vector alone were assayed, there was no dif-
ference in the amount of cytotoxicity. These ﬁndings suggest that the
cytotoxicity of the pp65-BLCL primed CTL cultures was speciﬁc for
CMV pp65 as well as for EBV BLCL, and that the selection marker
bacterial neomycin phosphotransferase was not immunogenic. This
CMV speciﬁc cytotoxicity appeared to be against pp65 only and was
HLA Class I-restricted, since 1) similar cytotoxicities were observed
against SF transduced with the pp65-encoding retrovirus or infected
with a pp65-encoding vaccinia virus, but not the control targets, and 2)
antibodies against HLA Class I but not HLA Class II inhibited more
than 50% of the pp65 targeted cytotoxicity. Thus, our preliminary data
suggested that this strategy might be used to generate bi-speciﬁc CTL
cultures in vitro.
ANALYSIS OF GVHD FOLLOWING ALLOGENEIC BONE MARROW
TRANSPLANTATION IN FASL DEFECTIVE AND NORMAL RECIPIENTS.
M. Mammolenti, M. Jones and R.B.Levy. Department of Microbiology
and Immunology, University of Miami School of Medicine, Miami, FL
33101
We are interested in understanding the involvement of cytotoxicity
following allogeneic bone marrow transplantation (BMT). To investi-
gate if the expression of functional FasL in recipients can effect the out-
come post transplant, MHC matched allogeneic BMT was performed
using FasL defective (B6.gld) or FasL normal (B6) recipients. Varying
numbers of unprimed C3H.SW T cells together with normal B6 TCD
marrow was injected into 9.0Gy recipients. Mice were monitored for
weight loss, survival and clinical signs of GVHD. Modest clinical
changes were identified in both groups. Transient weight loss also
occurred in both groups. In one experiment, B6.gld but not B6 recipi-
ents died after transplant with high numbers (4 x107) of C3H.SW T
cells. Subsequently, T cells from C3H.SW (H-2b) mice primed to B6
(H-2b) antigens were transplanted. Again, the kinetics and amount of
weight loss in the two groups were indistinguishable. No signiﬁcant dif-
ferences at 2 and 4 weeks post-BMT were apparent in the total num-
bers of cells in the thymus and spleen in B6.gld and B6 recipients. Phe-
notypic analysis demonstrated both groups of recipients had few DP
thymocytes and an inverted splenic CD4/CD8 ratio as well as few
B220+ cells in this tissue. Interestingly, skin involvement appeared to
occur more rapidly in the FasL-defective B6.gld recipients. Following
BMT with 1 x107 T cells, skin lesions appeared within 3-4 weeks in
B6.gld but not normal B6 (>40 days) recipients. BMT using higher
numbers of T cells again resulted in earlier and more severe skin
changes in B6.gld recipients. Histological analysis of skin and other
FasL expressing tissues is being examined. If host FasL expression post-
BMT is important, B6.gld recipients might exhibit more rapid lympho-
hematopoietic GVHD or target tissue destruction (e.g. skin, liver, GI)
and/or perhaps additional (ex. testes, eye) tissue involvement. The pre-
sent data suggest that other regulatory molecules or FasL expression by
donor populations may be sufﬁcient to regulate donor lymphoid cell
expansion post-BMT. However, FasL expression in skin may be capa-
ble of inhibiting pathogenesis in this tissue.
INDUCTION OF TRANSPLANTATION TOLERANCE ACROSS MAJOR AND
MINOR HISTOCOMPATIBILITY BARRIERS USING NON-MYELOABLATIVE
CONDITIONING WITH FLUDARABINE, LOW DOSE IRRADIATION, AND
CYCLOPHOSPHAMIDE
Leo Luznik, Laura W. Engstrom and Ephraim J. FuchsJohns Hopkins Oncology
Center, Baltimore, MD
Administration of cyclophosphamide (Cy) 2-3 days after cell transplan-
tation has been shown by multiple investigators to induce tolerance and
low-level (3-4%) chimerism across minor but not major histocompatibili-
ty barriers. In this model, ( 50 million donor cells must be administered
before Cy for tolerance to be induced. The goal of the current experi-
ments was to lower the cell dose threshold for the induction of tolerance
and to facilitate the induction of tolerance across major histocompatibility
complex (MHC) barriers. Treatment of animals with 200 cGy total body
irradiation (TBI) prior to transplantation lowered the tolerogenic dose to
10 million cells and increased donor cell chimerism to 20% following the
administration of Cy. However, this same regimen failed to induce toler-
ance in animals with major MHC antigen differences. Because of the
apparent rejection of MHC-incompatible cells, we have added ﬂudara-
bine to pretransplant irradiation to increase the degree of recipient
immunosupression. DBA/2 mice treated with Fludarabine 60 mg/M2 on
d.-3 and -2, 200 cGy TBI on d.O and Cy 200 mg/kg IP on d.3 (Flu-
XRT-Cy) accept minor + MHC antigen-incompatible B6-Ly5.2 marrow
grafts given on day 0. Chimerism at 4 and 8 weeks was minimal but
detectable with 10 million donor marrow cells, whereas 20 million donor
marrow cells induced approximately 65% donor T cell chimerism within
the spleen and thymus at 8 weeks after transplant. Addition of pre-trans-
plant Cy to this regimen (to generate “Flu-Cy-XRT-Cy”) further aug-
mented chimerism within the spleen and thymus to >95%. Donor
chimerism was detected in granulocytes and B cells as well. These data
suggest that tolerance and signiﬁcant chimerism with MHC and minor
antigen-incompatible cells can be readily achieved by preparing recipients
with a combination of ﬂudarabine, cyclophosphamide and low dose irra-
diation. This regimen may be easily adapted for non-myeloablative trans-
plantation using HLA-haploidentical donor-recipient pairs.
EX VIVO EXPANDED BONE MARROW PRODUCT IN COMBINATION
WITH LOW DOSE OF AUTOLOGOUS PBSC ENHANCES CLINICAL OUT-
COME.
R.K. Mandalam, J. Douville, 1P.J. Stiff, 2A.J. Pecora, R.D. Armstrong, and A.K.
Smith Aastrom Biosciences, Inc., 1Loyola University Medical Center, 2Northern
New Jersey Medical Center
Infusion of ex vivo expanded autologous bone marrow (BM) cells as the sole
source of rescue in myeloablative STAMP V chemotherapy treated breast cancer
patients results in short- and long-term hematopoietic and immune reconstitution
(Stiff et al., Blood 90:395a, 1997). BM cells obtained from a small volume aspirate
((40 mL) expanded using cytokine (PIXY321, Epo, Flt3-L) supplemented medium
and continuous perfusion results in a) formation of a stromal layer providing a
hematopoiesis supporting microenvironment b) expansion of stem and progenitor
cells, and c) passive purging of tumor cells. An automated clinical scale system
called the AastromReplicellTM Cell Production System has been developed to
implement the biology of the ex vivo expansion process under cGMP conditions.
More recently, ex vivo expanded BM cells generated (using conditions described
above) from a cryopreserved/thawed small volume whole BM sample ((1.5 x109
viable cells) were evaluated clinically in combination with a suboptimal PBSC
CD34+ dose. In a pilot study, breast cancer patients (Stage II-IV) received 10
(g/kg/day of G-CSF for 5 days with a small volume of BM collected for expansion
on day 3. The patients then went on to apheresis for PBSC collection with subse-
quent administration of the STAMP V regimen. Eight patients receiving the 0.5
x106 PBSC CD34+ cells/kg + AastromReplicell System expanded BM cells reached
ANC ( 500 and platelets ( 20,000 on median days of 10.5 and 13 respectively.
Seven patients receiving (0.5 to 2.0 x 106 PBSC CD34+ cells/kg + AastromRepli-
cell System expanded BM cells reached ANC ( 500 and platelets ( 20,000 on medi-
an days of 10 and 11 respectively. The period to reach these clinical recovery
thresholds are signiﬁcantly superior, particularly for platelet recovery, than those
reported for a similar dose of CD34+ PBSC alone. Additionally, patients undergo-
ing transplant with the combination of PBSC and Aastrom Replicell expanded BM
cells showed a median of 2 febrile days compared to the typical 4-6 febrile days
seen with PBSC transplants at these clinical sites. Use of the AastromReplicell Sys-
tem in combination with suboptimal PBSC CD34+ doses has the potential to yield
optimal recoveries for patients mobilizing poorly while also minimizing the risk of
reinfusion of contaminating tumor cells by both passive purging achieved during
the BM expansion process and reduction in the apheresis product as only low dose





INFILTRATING T-CELLS DURING LIVER GVHD SHOW A RESTRICTED
T-CELL REPERTOIRE.
D. Margolis, T. Janczak, L. McOlash, and J. Gorski. Medical College of
Wisconsin, Milwaukee, WI
Data from animal models has shown that hepatic graft versus host disease
may be mediated by donor T cells interacting with liver adhesion molecules
and/or other minor histocompatibility antigens. We hypothesized that T-
cell inﬁltrates within a liver biopsy during clinical GVHD would show a
restricted T-cell response because the T-cells would be responding to a lim-
ited number of antigens. The peripheral T-cell repertoire and the liver inﬁl-
trating T-cell repertoire was studied in a patient who initially developed skin
graft versus host disease with subsequent development of liver GVHD after a
matched sibling BMT for AML. Spectratype analysis of the peripheral blood
at the time of liver GVHD revealed that the patient had reconstituted a
complex peripheral T-cell repertoire as evidenced by CDR3 length hetero-
geneity presence in most of the T-cell families. The repertoire complexity
was skewed to one CDR3 length predominating in VB 5.3, 4, 7, 8, 15, and
6.1. Spectratype analysis on the liver biopsy sample revealed a limited inﬁl-
trate with an oligoclonal expansion in VB’s 2, 4, 7, 8. The T-cell inﬁltrate
was evaluated in more detail by sequencing the relevant expansions noted by
spectratype and then developing probes to the predominant CDR3
sequences found (clonotype). The clonotype probes were hybridized to the
peripheral blood and liver samples from the patient, a T-cell line developed
using T-cells in the peripheral blood at the time of the initial skin GVHD,
the donors’ blood and marrow, and controls. The results are: (A) The oligo-
clonal expansion in the blood in families VB15 and VB5.3 were derived from
the donor, are present in a T-cell line derived from the patient at the time of
the initial skin GVHD, but are not found in the liver; (B) The oligoclonal
expansion found in the liver in VB 7 and VB 4 were derived from the donor,
are not present in a T-cell line derived from the patient at the time of the ini-
tial skin GVDH and are present in the liver and the peripheral blood. These
results show that the T-cell inﬁltrate during liver GVHD is mediated by a
limited number of T-cells. These cells are different than T-cells expanded in
the peripheral blood during an acute skin GVHD reaction. This data is evi-
dence supporting the hypothesis that liver GVHD is a response to tissue spe-
ciﬁc minor histocompatibility antigens. Further work must be done to deﬁne
these antigens.
DONOR-DERIVED HEMATOPOIESIS IN LONG-TERM MARROW RECIPI-
ENTS.
Mathioudakis,G., Storb, R., McSweeney, PA, Gass, MJ, Lansdorp, PM, Brum-
mendorf, TH, Flowers, MED and Nash, RA. Fred Hutchinson Cancer Research
Center (FHCRC), Seattle, WA and Terry Fox Labs, Vancouver, BC.
Here we characterize donor-derived hematopoiesis in long-term (> 20 yrs)
allogeneic marrow recipients. Clinical status of hematopoiesis was deter-
mined from complete peripheral blood counts (CBC) and by chimeric analy-
sis using Y-chromosome fluoresence in-situ hybridization (FISH) or
microsatellite markers. Clonal status was examined by X-linked clonal analy-
sis using probes for the PGK and M27( genes and telomere length by termi-
nal restriction fragment (TRF) and by Flow-FISH analysis. At the time of
study, CBC were normal in all patients except one, who was pancytopenic
with high mean corpuscular volume (MCV), absolute neutrophil count
(ANC) of 400, platelet count of 40,000 and hematocrit of 34%. All but one
patient, who had mixed chimerism, were full chimeras (>96% donor), includ-
ing the patient with pancytopenia. We found that the recipients had shorter
telomeres ((TRF) compared to their donors, including the patient with pan-
cytopenia, who in fact had the highest degree of shortening ((TRF=1.7 kb).
All patients with female donors had polyclonal hematopoiesis as determined
by X-linked analysis. The ﬁrst patient identiﬁed with pancytopenia is the
third longest survivor of an allogeneic transplant at FHCRC, 27 yrs after
transplant for aplastic anemia (AA). He very recently received purified
CD34+ cells from his initial marrow donor. Very recently an additional
patient with late pancytopenia has been identiﬁed. He was transplanted more
than 20 years ago for AA and whereas his CBC was normal until recently, he
developed pancytopenia with a high MCV and normal B12 and folate levels.
Our ﬁndings indicate that the majority of long-term marrow recipients have
normal counts, polyclonal hematopoiesis and accelerated telomere shorten-
ing. There are, however, at least 2 long-term recipients with late donor-
derived marrow failure and marked telomere shortening, raising the issue of
late marrow dysfunction and potential correlation with telomeric loss. We
aim to expand our studies to include more patients and by estimating their
stem cell pool reserve by marrow cultures.
SYNGENEIC LYMPHOCYTE INFUSION (SLI) FOLLOWING ALLOGENEIC
BMT RESULTS IN A DELAY OF CLINICAL GVHD AND PROLONGED
RECIPIENT SURVIVAL: A MODEL FOR GVHD RESCUE.
L. Marks and R.B. Levy. Dept. of Microbiology and Immunology.Uni-
versity of Miami School of Medicine, Miami, FL 33101
Allogeneic bone marrow transplant (BMT) is the treatment of choice for a
wide variety of hematopoietic disorders, including malignancies. Graft-ver-
sus-host disease (GVHD) is currently the second most signiﬁcant cause of
morbidity and mortality following an allogeneic BMT. Experimental, as well
as clinical allogeneic BMTs involving donor-recipient MHC Class I/II dis-
parities result in acute GVHD. To determine if it is possible to rescue recipi-
ents from GVHD, we examined the efﬁcacy of a syngeneic lymphocyte infu-
sion (SLI) of BALB/C cells post-BMT in the B6 (H-2b) ( BALB/C (H-2d)
BMT model. BALB/C mice were irradiated with 8.25 Gy, and the following
day B6 bone marrow and 0.5 x 106 T lymphocytes were innoculated by i.v.
injection. The following groups of BALB/c cells (spleen and lymph node
cells that were either naive, or primed in vivo against B6) were infused at day
13 post-BMT: A-no cells (vehicle only); B-100 x106 primed cells, C-50 x106
primed cells; D-100 x106 naive cells; E-30 x106 primed cells that had been T-
cell depleted (TCD), and F-50 x106 primed cells that had been T-cell
enriched (TCE).
Survival at day 50 post-BMT was as follows: A-0%, B-100%, C-0%, D-
50%, E-0%, and F-25%. Mean survival time was >63 days in Gr.B, com-
pared to 40 days in Gr.A. Notably, the average weight of Gr.B mice stabi-
lized beginning at day 11 post-SLI, whereas Gr.A mice experienced
perpetual weight loss. Additionally, Gr.B mice showed a prolonged delay
before the onset of severe symptoms characteristic of GVHD (fur rufﬂing,
haunched posture, diarrhea) with an average time of onset of 56 days com-
pared to the Gr.A average time of onset of 36 days. The results have demon-
strated that SLI can induce an early increase in survival, and delay the onset
of the clinical GVHD process. We plan to pursue these results by examining
the mechanism of rescue and the role of timing of the SLI in this and other
BMT model systems.
PROSPECTIVE NEUROCOGNITIVE ASSESSMENT FOLLOWING BONE
MARROW TRANSPLANTATION: PART I. CHILDREN.
McCabe, MA, Shimoda, KC, Schuman, WB, Dinndorf, PA, Children’s
National Medical Center and George Washington University School of
Medicine, Washington D.C.
Bone marrow transplantation (BMT) includes preparative regi-
mens (i.e., total body irradiation, high dose chemotherapy) which
may be toxic to the developing nervous system. Prospective cogni-
tive and achievement testing has been analyzed for 25 survivors ((3
years of age) at 18-months, 19 survivors at 3-years, and 10 survivors
at 5-years post-BMT in relation to their baseline functioning.
Results suggest that BMT regimens in childhood may indeed be
associated with decline in cognitive and achievement scores for
some children. Non-parametric analyses suggest that risk factors
identiﬁed in the literature on neurocognitive outcome with child-
hood malignancies (i.e., diagnosis of ALL, previous craniospinal
radiation) also play a role in neurocognitive outcome following
BMT.
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PLATELET TRANSFUSIONS: UTILIZATION AND ASSOCIATED COSTS IN
A TERTIARY CARE HOSPITAL.
K.R. Meehan1, C.O. Matias1, S. Rathore2, S.G. Sandler1,3, J. Kallich4, J.
LaBrecque4, M.H. Erder4, K.A. Schulman2. 1Bone Marrow Transplant Program,
2Division of Clinical Economic Research Unit, 3Blood Bank, Georgetown University
Medical Center, Washington, DC 20007, 4Amgen, Inc., Thousand Oaks, CA
We performed a prospective study to evaluate the utilization of platelet
transfusions and compare resource use and costs among all admitting ser-
vices and diagnoses in a tertiary care hospital for a 6-month period. Inpa-
tients receiving platelet transfusions between July and December 1996
were followed prospectively. Clinical and ﬁnancial data were collected,
categorized and crosschecked according to patient admitting service and
principal diagnoses using ICD-9 codes. During the study period, 1,957
platelet transfusions were administered to 247 inpatients. Seventy-ﬁve per-
cent of all platelet transfusions were single donor (apheresis) units. Of
1,468 single donor platelet units and 489 random donor platelet units
transfused, 86% were administered to bone marrow transplant (BMT)
patients and patients with hematological malignancies/ diseases. These
two admitting services accounted for 61.5% of all hospital inpatient costs
during this time period. Of 247 inpatients who received platelet transfu-
sions, 51 became refractory to platelet transfusions (20.6%); BMT patients
(n = 29) and Leukemia/Lymphoma patients (n = 14) comprised the major-
ity of these patients. Platelet-refractory patients received 57.4% and
69.2% of all random and single donor platelet transfusions. On average,
the hospital stay was longer (33.3 days versus 14.5 days) and inpatient
resource use and hospital costs were more than three times higher for
patients refractory to platelet transfusions. Platelet-refractory patients use
signiﬁcantly more single donor platelets and incur more hospital costs
than nonrefractory patients. Strategies that would decrease the use and
costs of platelet transfusions include lowering the threshold to 10,000(L
for the administration of prophylactic platelets and the increased use of
random donor platelet transfusions respectively.
CHARACTERIZATION AND OUTCOME OF “HARD TO MOBILIZE” LYM-
PHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANS-
PLANTATION.
M. Sugrue, K. Williams, S. Peracha, S. Khan, J.R. Wingard, J.S.
Moreb. University of Florida, Gainesville, FL.
A “hard to mobilize” patient was defined as one in whom ( 1x106
CD34+ cells/kg cannot be obtained after two consecutive large volume
apheresis. In the present study, data from all lymphoma patients,
Hodgkin’s and non-Hodgkin’s, enrolled consecutively for treatment
between June 1996 and June 1998 were analyzed. A total of 44 patients
were studied and 21 (48%) met the deﬁnition of “hard to mobilize”
(Group I). Main differences between the “good mobilizers” (Group II)
and Group I were in the median number of prior treatments (2 vs 3,
respectively) and the frequency of radiotherapy use (32 vs 47%, respec-
tively). Of Group I, 7/21 (33%) patients were unable to achieve a mini-
mal dose of ( 1x106 CD34+ cells/kg even after a second cycle of aphere-
sis and/or bone marrow (BM) harvest (n=5). Overall, 11/21 (52%)
required an additional mobilization and/or BM harvest. Only 3/21
(14%) patients were able to meet target cell dose of ( 2.5 x106 CD34+
cells/kg (median of 4 apheresis). In contrast, 87% of Group II achieved
the target dose with a median of 2 aphereses. Initial mobilization proto-
col was 10 (g/kg of G-CSF alone for both groups. The median WBC
count on the day of ﬁrst apheresis was 21.3x103/(l for Group I versus
39.7x103/(l for Group II and the median CD34+ cell content of the ﬁrst
apheresis yield was 0.08% versus 0.46%, respectively. Nineteen patients
in Group I and all Group II completed treatment with a median time to
engraftment of AGC>500/(l of 12 and 11 days, respectively and platelet
>20x103/(l of 31 and 13 days, respectively. Outcome analysis revealed
that 6/19 patients in Group I died of relapse within less than a year
from transplant while only 2/23 of Group II died of the same causes.
There were no treatment related deaths in either group. Our results
show that definite early predictive features for “hard to mobilize”
patients cannot be recognized and that poor mobilization may indicate
worse prognosis and outcome for lymphoma patients.
IMPACT OF TRANSPLANTATION ON THE DELIVERY OF LOCAL RADIA-
TION IN HIGH RISK BREAST CANCER.
HCF Moore, R Mick, C Sickles, P Mangan, L J Solin, E Glatstein, G Buzby, KR
Fox, SM Luger, DL Porter, LM Schuchter, E Loh, S Schuster, L Silberstein, EA
Stadtmauer U of PA Cancer Center; Philadelphia, PA
High-dose chemotherapy with stem cell transplant is used increasing-
ly in the treatment of breast cancer. Because even high-risk patients
may be cured with surgery, conventional adjuvant chemotherapy and
local radiation, it is important to assess the interaction of transplant
with the delivery of standard aspects of treatment. Between June 1992
and December 1997, we treated 103 women with high dose Cytoxan
and Thiotepa and stem cell support for stage II or IIIa breast cancer
involving (4 axillary lymph nodes following surgery and conventional-
dose adjuvant chemotherapy. Disease-free and overall survival rates at
the median follow-up time of 18 months were 77% (+/-4%) and 83%
(+/-4%) respectively. Twenty patients (19.4%) had undergone local
radiation therapy prior to transplant. Of the remaining 83 patients, 6
did not receive radiation therapy because of thrombocytopenia (3
patients), transplant toxicity (2 patients) or disease progression (1
patient). Median time from deﬁnitive surgery to completion of radia-
tion therapy was 34.6 weeks (range 10.9 to 50.1 wks.) for patients irradi-
ated prior to transplant and 43.4 weeks (range 26.1 to 76.1 wks.) for
patients irradiated after transplant. The mean radiation dose delivered
was 5328 cGy. Sites of ﬁrst relapse were known for 26 of 27 patients
who progressed; of these, 5 had locoregional recurrence alone as their
ﬁrst site of failure. For patients irradiated prior to transplant, 3 of 7
(43%; 95% CI 6% to 80%) ﬁrst recurrences were local, while 2 of 19
(10.5%; 95% CI 0% to 24.5%) ﬁrst recurrences were local alone in
patients for whom radiation was delayed or omitted. While tumor char-
acteristics were similar in the two groups, no increase in the relative rate
of local recurrence was observed in patients who did not receive early
radiation. No difference in disease-free survival was seen between the
two groups of patients. Deferring radiation therapy until after trans-
plant does not appear to adversely impact patterns of recurrence or dis-
ease free-survival.
PREEMPTIVE THERAPY BASED ON CYTOMEGALOVIRUS ANTIGENEMIA
AFTER BONE MARROW TRANSPLANTATION.
Takehiko Mori, Sahoko Matsuoka, Reiko Watanabe, Akaru Ishida,
Masatoshi Wakui, Shinichiro Okamoto, Yasuo Ikeda Div. of Hematol-
ogy, Keio Univ. Sch. of Med., Tokyo, Japan
There have been trials for prevention of cytomegalovirus (CMV) diseases,
either using prophylactic or preemptive approach with ganciclovir (GCV),
which were not uniformly successful. To treat the patients at highest risk of
CMV diseases and minimize the toxicity of GCV, we designed a preemptive
therapy based on the degree of CMV antigenemia and acute GvHD. After
engraftment, CMV antigenemia was routinely monitored weekly and once it
revealed positive, monitored twice a week. If CMV antigenemia at a level of
10 or more positive cells in 2 slides in patients with no or grade I acute
GvHD, or any positive cells in patients with Grade II-IV acute GvHD was
detected, intravenous GCV was initiated at a dose of 10 mg/kg/day for 14
days. If antigenemia was negative after 14-day therapy, GCV was discontin-
ued. If not, GCV was continued at a dose of 5 mg/kg/day or less until anti-
genemia revealed negative. Fifty two consecutive CMV-seropositive recipi-
ents of allogeneic BMT or recipients of CMV-seropositive allografts were
entered into this study and 48 were evaluable. Most of the patients had
hematologic malignancies. Twenty three received marrow from HLA-iden-
tical siblings and 25 from unrelated donors. Prophylaxis for GvHD was
attempted with cyclosporine or tacrolimus with short term methotrexate in
most cases. All patients received CMV hyperimmunoglobulin weekly, and
HSV-seropositive patients also received intravenous acyclovir (from Day-3
to +14). In 48 evaluable patients, 22 patients (46%) developed CMV antigen-
emia and 8 out of the 22 patients (45%) developed CMV disease (7; gas-
troenteritis, 1; retinitis). All 8 patients had Grade II-IV GvHD. In 6 patients,
CMV antigenemia became positive after the manifestation of CMV diseases.
Incidence of CMV antigenemia/disease was signiﬁcantly higher in patients
with Grade II-IV GvHD than those with Grade 0-I (P<.05). CMV pneumo-
nia and CMV-associated deaths were not observed. Neutropenia due to
GCV was observed in 17% of patients treated, which was successfully treated
with G-CSF. These results suggest that our preemptive approach is quite
effective for preventing CMV pneumonia, which is often fatal, but not effec-





TRANSPLANTATION-RELATED MORTALITY AND TREATMENT OUT-
COME IN NON-HODGKIN’S LYMPHOMA PATIENTS WITH ‘POOR’
MOBILIZATION OF PERIPHERAL PROGENITOR CELLS.
Sunil A. Reddy, Sandra J. Horning, Karl G. Blume, and Keith E. Stock-
erl-Goldstein. Stanford University Medical Center
Many groups of investigators have reported that a minimum of 2 x106 CD34+
cells/kg are necessary to allow rapid engraftment of white blood cells and platelets
following high-dose therapy and autologous peripheral blood progenitor cell
(PBPC) support. This analysis was performed to evaluate the outcomes of patients
who are ‘poor’ mobilizers of PBPC’s who collect < 2 x 106 CD34+ cells/kg versus
‘good’ mobilizers who collect ( 2 x 106 CD34+ cells/kg in a single apheresis.
Methods. One hundred seventy-two consecutive patients with non-Hodgkin’s lym-
phoma (NHL) were treated with high-dose therapy and autologous hematopoietic cell sup-
port between 8/1/94 and 7/31/98. Patients received cyclophosphamide and G-CSF fol-
lowed by apheresis of PBPC’s. The PBPC’s were separated on a Percoll gradient and
purged using monoclonal antibodies and complement.
Results. The day of last follow-up is 11/30/98, with a minimum follow-up of
132 days and a median follow-up of 2.4 years. Thirty-four patients were ‘poor’
mobilizers of PBPC’s (19.8%) with a median collection of 0.84 x 106 CD34+
cells/kg (range 0-1.9 x 106 CD34+ cells/kg). One hundred thirty-eight patients
were ‘good’ mobilizers of PBPC’s with a median collection of 4.6 x 106 CD34+
cells/kg (range 2.0-29.1 x 106 CD34+ cells/kg). The only signiﬁcant predictive fac-
tor for ‘poor’ mobilization is that they are more likely to be women (65%) than
men (35%, p=0.003). ‘Poor’ mobilizers received autografts utilizing purged bone
marrow in 15 (44%), purged PBPC’s in 14 (41%) and purged bone marrow plus
purged PBPC’s in 5 (15%). All ‘good’ mobilizers were autografted utilizing purged
PBPC’s alone. Engraftment of white blood cells and platelets was signiﬁcantly
slower in ‘poor’ mobilizers. There was a signiﬁcantly higher transplant-related
mortality (TRM) in the ‘poor’ mobilizers, 11%, compared with ‘good’ mobilizers,
3%, p=0.05. Three-year Kaplan-Meier estimates of event-free survival (EFS),
overall survival (OS) and relapse (REL) are presented and demonstrate no signiﬁ-
cant differences. ‘Good’ mobilizers had a respective EFS, OS, and REL of .47, .59,
and .50 as compared to ‘poor’ mobilizers values of .41, .55, and, .48. The corre-
sponding p values are .60, .37, and .72. Data evaluating predictors of ‘poor’ mobi-
lization and an economic analysis associated with the costs of ‘poor’ mobilization
will also be presented.
Conclusion. Patients who are ‘poor’ mobilizers of PBPC’s have equivalent EFS,
OS and REL following high-dose therapy and autologous hematopoietic support,
however, TRM is signiﬁcantly higher in this group.
ALLOGENEIC MARROW TRANSPLANTATION FOR SEVERE APLASTIC
ANEMIA (SAA) - A TWENTY YEAR PERSPECTIVE.
M. O’Donnell, W. Hu, A. Stein, J. Palmer, M. Amylon, N. Chao, P. Parker, D.S.
Snyder, A. Nademanee, E.P. Smith, K. Margolin, R. Spielberger, A. Kashyap, J.
Rosenthal, R. Krance, K. Blume and S.J. Forman. City of Hope National Medical
Center and Stanford University
A retrospective chart review of 88 patients transplanted from sibling donors
for SAA between May 1975 and Dec. 1997, was conducted to assess impact of
preparative regimens and GVHD prophylaxis as well as pre-BMT factors such
as age, prior transfusion and donor/recipient sex match on engraftment and
overall survival. Preparative regimens were Cytoxan (CY) alone 53 pts, CY+
radiation 10 pts and CY + ATG 25 pts. GVHD prophylaxis was MTX and
prednisone (PSE) 15 pts, Cyclosporin (CSA)/PSE 33 pts and CSA + MTX (+/-
PSE) 37 pts. Median age at BMT was 23 yrs (4-47) and median time to BMT
was 25 days (10-3600 d). Six pts (7%) had either initial (2 pts) or late (4 pts)
graft failure among 84 pts surviving beyond 14 d; the late graft failures
occurred between d 130 and 370 post BMT. All graft failures occurred in pts
prepared with CY alone; however, neither preparative regimen (p=0.10)
GVHD prophylaxis or any pre BMT pt characteristics predicted for graft fail-
ure. Five graft failure pts received ATG and CY or nitrogen mustard for sec-
ond BMT and all achieved successful engraftment. The incidence of acute
GVHD (grade 2-4) has decreased signiﬁcantly in the last 20 years from 75% in
pts receiving MTX/PSE to 8% in pts receiving CSA/MTX in conjuction with
CY + ATG for conditioning. The overall incidence of acute GVHD (grade 2-
4) was 31%; this did have a signiﬁcant impact on survival at d 100 (91% for
grade 0-1 and 83% for grade 2-4 p = 0.01). Chronic GVHD developed in
38/74 pts (51%) it progressed from acute in 13 pts and appeared de novo in 25
of these pts. Chronic GVHD was limited in 21 pts and extensive in 17 pts. The
incidence of chronic GVHD has decreased to 25% in the last ﬁve yrs. Overall,
survival at 2 yrs has improved dramatically in the last 20 yrs from a 43% in the
1970s, to 78% in the 1980s and 88% currently. No one factor has signiﬁcantly
affected overall survival independently although there are trends suggested by
better GVHD prophylaxis (90% 2 yrs OS with CSA/MTX + 1-PSE vs 79%
for CSA/PSE and 67% MTX/PSE) and improved conditioning (88% 2 yrs
OS with CY/ATG vs 75% for CY alone. Age over 30 yrs was the only pt
dependent factor which predicted for a lesser survival at 2 yrs (65% vs 85% for
pts less than 30 yrs) (p = 0.01). Allogeneic BMT offers an excellent outcome
with good quality of life in young patients with SAA.
VALIDATED PREDICTIVE MODEL FOR RELAPSE AFTER HIGH-DOSE
CHEMOTHERAPY (HDC) WITH AUTOLOGOUS STEM-CELL SUPPORT
(ASCS) FOR HIGH-RISK PRIMARY BREAST CANCER (HRPBC).
Y Nieto, PJ Cagnoni, EJ Shpall, X Xu, RB Jones, SI Bearman. University of Col-
orado BMT Program
A retrospective analysis of 176 HRPBC pts (deﬁned by 10+, 4-9 involved
nodes, or inﬂammatory breast cancer [IBC]), treated with HDC and ASCS,
was performed. All pts received high-dose cyclophosphamide, cisplatin and
BCNU (STAMP-I), followed by radiotherapy and tamoxifen, if either ER+
or PR+. These pts had survived the transplant, and were either relapse-free
at (2 years of follow-up (F-U), or had relapsed at any time post-HDC. Medi-
an F-U is 45 (range 12-74) months. We deﬁned nodal ratio as the quotient
(number of (#) positive (+) nodes / # sampled nodes(. An association was
found between risk of relapse and nodal ratio (p=0.001), ER(-) (p=0.001),
PR(-) (p<0.01), tumor size (p<0.01), stage (p=0.01), tumor grade (p<0.05),
and clinical IBC (p<0.05). The following did not correlate with relapse:
absolute # of + nodes, pathologic IBC (dermal lymphatic involvement), vas-
cular or lymphatic vessel invasion, multifocality, extensive intraductal com-
ponent, DNA ploidy, S-phase fraction, lymphatic extranodal extension, size
of involved nodes, menopausal status, gender, bilateral synchronous tumors
and family history of BC. In a multiple logistic regression analysis, nodal
ratio, size and ER/PR negativity (both ER and PR negative) were indepen-
dent predictors. A scoring system was derived:
Score = (size x 0.15) + (ratio x 3.05) - (ER/PR x 1.19).
In this formula, size is entered in cm and ER/PR is assigned “0” if both
negative, and “1” if either one or both are positive. Scores of <2.41 or >2.41
allocate pts to low or high-risk groups, with probabilities of relapse of 15%
and 85%, respectively. Differences in relapse-free (RFS) or overall survival
(OS) between pts with a high and a low score are highly significant
(p<0.000001). The model has these properties: sensitivity/specificity:
60%/90%, positive/negative predictive value: 65%/88%, accuracy: 83%.
The model was validated in an independent sample of 244 HRBC pts
treated at Duke University with STAMP-I. The differences in RFS and OS
between low- and high-score pts were highly signiﬁcant (p<0.000001).
This model will be used to select high-score patients for future research.
TREATMENT OF ADVANCED MYELODYSPLASTIC SYNDROME (MDS)
WITH A REGIMEN INCLUDING RECOMBINANT HUMAN GRANULOCYTE
COLONY-STIMULATING FACTOR (G-CSF) PRECEEDING ALLOGENEIC
BONE MARROW TRANSPLANTATION.
Shinichiro Okamoto1, Satoshi Takahashi2, Masatoshi Wakui1, Akaru Ishida2, Ryuji Tanosaki1,
Yasuo Ikeda1, and Shigetaka Asano2 Keio BMT Program, School of Medicine, Keio University1,
The Institute of Medical Science, The University of Tokyo2, Tokyo, Japan
Treatment of MDS generally has been unsatisfactory, and allogeneic bone
marrow transplantation (BMT) is currently the only curative treatment for
MDS resulting in reported 19% to 56% disease-free survival (DFS) rates.
However, even with an allogeneic BMT, patients with advanced disease
morphology (RAEB or RAEB-T) or MDS-related secondary AML (sAML)
had a higher relapse rate and a lower DFS rate after transplantation com-
pared with less advanced diseases. To investigate whether the myeloid cell-
speciﬁc action of G-CSF can be used to accomplish more effective eradica-
tion of myeloid leukaemic cells, we have administered G-CSF
simultaneously with pretransplantation conditioning consisting of total body
irradiation (TBI) and cytosine arabinoside (Ara-C). We have examined the
efficacy of this conditioning regimen in 13 patients with RAEB (n=4),
RAEB-T (n=1), or sAML (n=8). The patients were between 18 and 53 years
old (median, 43). TBI (total dose 12 Gy) was given in 4 to 6 fractions on days
-9 and -8 or days -10, -9, and -8. Ara-C was administered i.v. over 2h at a
dose of 3 g/m2 every 12h for 4 consecutive days between days -5 and -2.
Recombinant human G-CSF was administered by continuous infusion at a
dose of 5 (g/kg/day. Infusion of G-CSF was started 12h before the ﬁrst dose
of Ara-C and stopped at the completion of last dose of Ara-C. All patients
received marrow transplantation from HLA-identical sibling donors. Twelve
patients received cyclosporine and one patient received tacrolimus in combi-
nation with methotrexate (MTX) as prophylaxis against GVHD. Engraft-
ment and complete remission were obtained in all cases. No regimen-related
deaths occurred, and no side effects related to the addition of G-CSF were
observed except for transient mild bone pain. At a median follow-up time of
39 months, the projected 5-year disease-free survival and 5-year overall sur-
vival were 67.7% and 75.5%, respectively, with only one case showing cyto-
genetic relapse. Projected relapse and nonrelapse mortality rates at 5 years
were 8.3% and 26.7%, respectively. This preparative regimen including G-
CSF is feasible, and preliminary results seem to be encouraging. However, a
larger trial is clearly warranted to evaluate its efﬁcacy.




B B & M T
INVESTIGATION OF THREE C-MYC RETROVIRUS-TRANSFORMED
MYELOID LEUKEMIA LINES FOR POTENTIAL SHARED TUMOR ANTI-
GENS IN A GRAFT-VERSUS-LEUKEMIA MODEL.
A. Patterson, M. Hsieh, and R. Korngold. Kimmel Cancer Institute,
Thomas Jefferson Medical College, Philadelphia, PA 19107
A c-myc retrovirus-transformed myeloid leukemia line,
MMB3.19, was constructed to investigate graft-versus-leukemia
(GVL) activity in a syngeneic and allogeneic murine bone marrow
transplantation (BMT) model. It was previously determined in this
model that leukemia-presensitized CD4+-enriched T cells are capa-
ble of mediating GVL activity to MMB3.19 challenge while mini-
mizing graft-verus-host disease (GVHD). Two other similarly
derived myeloid leukemia lines, MMB1.10 and MMB2.18, were
developed to investigate potential shared tumor antigens in this
GVL model. Morphologically, all 3 tumor lines are blastic with a
high cytoplasmic to nuclear ratio. MMB2.18 demonstrates many
dendritic processes while MMB 1.10 and 3.19 are more rounded.
Flow cytometric analysis of the 3 leukemia lines revealed surface
molecule expression of Mac-1, Mac-2, F4/80, LFA-1, B7-2, H-
2Kb, macrophage scavenger receptor, and B7-1 (only MMB2.18
and 3.19). In vitro cross-proliferation studies in which MMB3.19-
primed splenocytes were restimulated with either MMB1.10, 2.18,
or 3.19 demonstrated that splenocytes proliferated upon restimula-
tion with MMB1.10 or 3.19, but not MMB2.18. Furthermore, sur-
vival GVL assays using donor MMB3.19-primed CD4+ T cells or
unfractionated T cells and subsequent leukemic challenge with
either MMB1.10, 2.18, or 3.19 showed increased survival in groups
receiving MMB1.10 or 3.19, but not 2.18. These data suggest that
MMB1.10 and 3.19 may express a common tumor antigen(s) while
MMB2.18 lacks such cross-protective characteristics.
ABSOLUTE NUMBER OF CD 34 + CELLS IN PERIPHERAL BLOOD PRE-
DICTS SUCCESSFUL APHERESIS COLLECTION OF PROGENITOR CELLS
IN INFANTS AND CHILDREN.
S. Kelly, C. Rollo, K. Prothe, R. Quinones, N. Foreman, R. Giller. The
Children’s Hospital / University of Colorado Health Sciences Center,
Denver
Peripheral blood progenitor cell harvests in pediatric oncology
patients sometimes result in products which contain suboptimal
numbers of CD34+ cells. This necessitates repeat procedures in
order to achieve a dose of progenitor cells sufficient to rescue
hematopoietic function. Therefore, we undertook a study to deter-
mine if the absolute number of CD34+ cells in peripheral blood
predicted the yield of CD34+ cells in the apheresis product. Efﬁ-
cient collection was deﬁned as a yield of ( 1.0e6 CD34+ cells/kg per
apheresis. Data was compiled from 42 apheresis procedures in 14
patients over a period of one year and analyzed using standard
regression analysis. CD34+ content of peripheral blood and
apheresis product was determined by ﬂow cytometric analysis using
the ISHAGE technique. Absolute CD34+ cells/ul was deﬁned as
WBC multiplied by percent CD34+ events.
Our analysis showed that 20 out of 24 harvests with an absolute
CD34+ count <10/ul resulted in a product CD34+ dose < 1.0e6/kg.
Regression analysis did not show linear correlation between
CD34+ content in peripheral blood and content in the ﬁnal prod-
uct for low absolute CD34+ counts (<10/ul). In contrast, at an
absolute CD34+ count (10/ul, only 3 out of 18 harvests failed to
yield a dose of ( 1.0e6/kg. Moreover, regression analysis showed
correlation between absolute CD34+ count and product yield for
absolute CD34+ counts (10/ul. The ability of peripheral blood
absolute CD34+ to predict apheresis yield was statistically signiﬁ-
cant (chi square; p<0.01). These results suggest that absolute
peripheral blood CD34+ count can be used to determine the opti-
mal time to collect progenitor cells in pediatric oncology patients.
RAPID AND DURABLE ENGRAFTMENT IN TWO PATIENTS WITH HIGH
RISK CML USING UNEXPANDED AND EXPANDED UMBILICAL CORD
BLOOD STEM CELLS.
A.L. Pecora, P. Stiff A. Jennis, S. Goldberg, R. Rosenbluth, P. Price, J. Douville,
R. Armstrong, A. Smith and R. Preti. Hackensack University Medical Center,
Hackensack, NJ; Loyola University Medical Center, Maywood, IL; and Aastrom
Biosciences, Ann Arbor, MI
Unrelated donor cord blood transplants in patients with a diagnosis
of CML and those receiving a low nucleated cell dose, in the HLA
mismatched setting, and in older patients, are associated with a greater
likelihood of delayed engraftment, graft failure, and non-relapse trans-
plant related events, respectively. In an attempt to improve on these
outcomes we treated two patients with CML; a 48 year old (107 kg)
male (pt.1) in early recurrent blast crisis and a 56 year old (72 kg)
female (pt. 2) in accelerated phase, with fractionated TBI (1200 cGy),
ATG (90 mg/kg) and cyclophosphamide (120 mg/m2), using unex-
panded and ex-vivo expanded unrelated cord blood. The cord blood
units were thawed and divided with approximately 90% of the unex-
panded unit infused on day 0 (pt. 1: 6/6 match; 1.1x107/kg) (pt. 2: 5/6
match; 1.0x107/kg). The remaining cells (pt. 1: 1.5x108; pt. 2: 1.3x108)
were expanded in AastromReplicell perfusion bioreactors for 12 days,
perfused with media containing PIXY, Flt3, and erythropoietin and
then infused (pt. 1: 3.4x108; pt. 2: 2.3x108). Prophylaxis for infection
and GVHD included oral ciprofloxacin, low dose amphotericin,
cyclosporine and prednisone. Patient one engrafted rapidly (neu-
trophils 500 and 1000 @ day 31 and 33: platelets 20, 50 and 100 @ day
52, 92, 147), had no signiﬁcant adverse transplant related events except
for transient CHF, no GVHD and remains in a cytogenetic remission
(100% donor) @ 13months. Patient two also engrafted rapidly (neu-
trophils 500 and 1000 @ day 25 and 34: platelets 20 @ day 60), had no
signiﬁcant transplant related events (never required i.v. antibiotics), no
GVHD, and remains in a cytogenetic remission (100% donor) @ day
80. In conclusion, ex-vivo expanded cord blood stem cells appear to
promote hematopoietic engraftment and reduce adverse transplant
related events in high risk unrelated cord blood transplant recipients,
warranting further investigation.
TACROLIMUS VERSUS CYCLOSPORINE IMMUNOSUPPRESSION:
RESULTS IN ADVANCED STAGE DISEASE PATIENTS WITH COMPARI-
SON TO HISTORICAL CONTROLS
D. Przepiorka1, M. Horowitz2, P. Bartels3, D. Buell3, MJ. Zhang2, W. Fitzsim-
mons3, J. Erdman3, C. Huang3, E. Hodosh3, R. Maher3, J. Wingard4 1Texas Chil-
dren’s Hospital, Houston, TX. 2IBMTR, Milwaukee, WI. 3Fujisawa Healthcare, Inc.,
Deerﬁeld, IL. 4U of Florida, Gainesville, FL
A Phase III comparative trial of tacrolimus- versus cyclosporine-based
graft-versus-host disease (GVHD) prophylaxis for HLA-identical sibling
bone marrow transplantation showed less GVHD but poorer survival in the
tacrolimus arm. However, a signiﬁcantly greater proportion of patients with
advanced stage disease were randomized to tacrolimus-based therapy. To
further evaluate the comparability of treatment arms in this study, the Inter-
national Bone Marrow Transplant Registry (IBMTR) database was used to
select matched controls for patients with advanced disease in the two arms of
the randomized trial. All controls received cyclosporine-methotrexate thera-
py at a North American center between 1990 and 1995 following receipt of
bone marrow from an HLA-identical sibling donor. Two controls were
identiﬁed for each of 100 of the 116 advanced disease patients in the Phase
III trial. Controls were matched for age (within 5 years), disease, and pre-
transplant disease status.
Consistent with the study results, the Kaplan-Meier estimate of Grade II-
IV acute GVHD was signiﬁcantly lower (p<0.01) in tacrolimus-treated clini-
cal trial patients compared with their matched IBMTR controls (28% versus
50%, respectively). Two-year survival for tacrolimus-treated clinical trial
patients was similar to their matched controls (27% versus 24%, respective-
ly). Both Grade II-IV acute GVHD and 2-year survival of the cyclosporine-
treated clinical trial patients were similar to their matched controls (acute
GVHD: 58% versus 45%, respectively; survival: 42% versus 45%, respec-
tively). However, the IBMTR controls matched to the tacrolimus group had
significantly poorer (p<0.01) 2-year survival than the IBMTR controls
matched to the cyclosporine group (24% versus 45%, respectively). These
results support the hypothesis that the survival difference in the Phase III
trial resulted from an imbalance in the underlying risk factors for death in





THE EFFECT OF SEQUENTIAL EX VIVO CYTOKINE EXPOSURE ON THE
GENERATION OF DENDRITIC CELLS FROM MOBILIZED CD34+ BLOOD
PROGENITOR CELLS.
Roman-Unfer S, Potter T, Quinones R, McNeice IK, Smith M, Steele A, Stoltz J,
Cagnoni PJ, Bearman SI, Jones RB, Nieto Y, Shpall EJ. U of Colorado, Denver,
CO
Dendritic cells are professional antigen-presenting cells that play a crucial
role in the immune response. Previous studies using dendritic cells generated
from peripheral blood mononuclear cells (PBMCs) have revealed two func-
tionally distinct subsets of DCs (immature vs. mature) that differ in both
function and phenotype. Immature DCs are typically generated in the pres-
ence of GM-CSF and IL-4 and are efﬁcient in antigen uptake and process-
ing. Following exposure to TNF-(, these cells mature and have an increased
allo-MLR, as well as a decreased ability to take up and process antigen. In
this study, PBPCs were collected from patients following mobilization with
granulocyte stimulating factor (G-CSF). The CD34+ cells were immuno-
magnetically isolated from a single apheresis product with the Baxter Isolex
300i device. These CD34+ cells were resuspended in X-vivo 15 medium con-
taining GM-CSF (50 ng/ml) and SCF (20 ng/ml) at a ﬁnal cell concentration
of 1.0 x 106 cells/ml, and then incubated at 37(C in 25 cm2 tissue culture
ﬂasks (Costar; Cambridge, MA) for two weeks. TNF-( (10 ng/ml), was then
added and the cells were incubated for an additional week. This method
resulted in product at week two where none of the cells exhibited typical DC
morphology on cytospin and expressed the following markers upon flow
cytometric analysis: CD11c (40-50%), HLA-DR(7-13%), CD40(1-2%), and
CD4 (0.1-0.2%). Functionally these cells did not exhibit enhanced allo-
MLRs. Following the exposure of these cells to TNF-( for one week, 30% of
these cells exhibited typical DC morphology on cytospin and revealed
enhanced expression of HLA-DR (31%), CD11c (60-70%), CD40 (13-
34%), and CD4 (7-23%) upon ﬂow cytometric analysis. In addition these
cells were capable of eliciting a potent allogeneic mixed lymphocyte
response, with stimulation indices greater than 100-fold when used at a ratio
of 1 DC per 100 peripheral blood lymphocytes (PBL). Results of antigen
uptake studies will be presented.
VISUALIZING THE KINETICS OF TUMOR CELL CLEARANCE IN LIVING
ANIMALS.
T.J Sweeney, V. Mailander, A.A Tucker, A.B.Olomu, C.H. Contag, R.S. Negrin,
Department of Medicine and Department of Pediatrics, Stanford University School
of Medicine, Stanford, California
Our laboratories have recently developed a non-invasive method for moni-
toring tumor progression in the living animal. Tumor cells were tagged with
the bioluminescent reporter gene luciferase and engrafted into irradiated
mice with severe combined immunodeﬁciency (SCID). Growth characteris-
tics of the tumor could be followed by the use of an intensiﬁed charge cou-
pled device (ICCD) camera. Bioluminescence, detected externally, was pro-
portional to cell number over 4 orders of magnitude. We used this
methodology to study the in vivo effects of a novel immunotherapy and stan-
dard chemotherapy against a luciferase tagged human cervical cancer cell line
(HeLa). These bioluminescent target cells were injected intraparitoneally
(ip) into 7 groups of 7 irradiated SCID mice each. 3 groups of mice were
treated with a population of human T cells expanded ex vivo, termed
cytokine induced killer (CIK) cells. The cells have potent anti-tumor activity
against a variety of human lymphoma cell lines both in culture and engrafted
into SCID mice. These cells are derived from T cell precursors and co-
express the T cell marker CD3 and NK marker CD56. Animals were treated
with either a 100:1 E:T ratio on days 1 and 7, a 1000:1 E:T ratio on day 1
alone, or 1000:1 E:T ratio on days 1 and 7. 3 of the groups were treated with
chemotherapy, either cyclophosphamide, 5-ﬂuorouracil or cisplatin. The last
group received PBS as a control. Mice were imaged weekly for 4 weeks and
tumor growth was measured by following the relative intensity of the light
emitted from the tumors. All the mice treated with PBS showed a graded
increase in light with time. The mice treated with CIK cells revealed attenu-
ated tumor growth in all three groups with several mice in the 1000:1 E:T
ratio groups demonstrating complete clearance of tumor signal throughout
the 4 week experimental period. The mice treated with 5-ﬂuorouracil and
cisplatin demonstrated a reduction of light intensity compared to control
animals. In contrast, cyclophosphamide had little in vivo activity. PCR analy-
ses of long term survivors in the cisplatin treated group failed to demonstrate
residual tumor. This novel, noninvasive system allowed sensitive, real time
spatiotemporal analyses of neoplastic cell growth and facilitated rapid opti-
mization of effective treatment regimens.
EFFECT OF MOLECULAR TYPING OF HLA CLASS I ANTIGENS ON
SEVERE ACUTE GVHD FOLLOWING UNRELATED BMT.
Rugo HS, Sayre P, Capper J, Damon L, Ries C, Linker C. University of Califor-
nia, San Francisco
We performed DNA typing on class I antigens from patient and donor after
unrelated BMT complicated by severe early acute GVHD to assess the impact of
mismatching. A 49 y.o. male with CML underwent matched unrelated donor
BMT. Diagnosis of CML was made 8 months prior to BMT; a 5 month trial of
interferon was poorly tolerated. Patient and donor were typed for class I, A and B
loci, by standard lymphocytoxicity using local and commercial typing trays. The C
locus was typed using a commercial sequence speciﬁc priming (SPP) kit. Class II





a single mismatch at C locus allele. The donor was female, 35 y.o., G1P1 and A+.
The patient was O+; both patient and donor were CMV negative. Marrow was
depleted of red cells using the Cobe Spectra cell separator. Following 1200 cGy TBI
and 120 mg/kg cyclophosphamide, 0.38 x 108 mononuclear cells/kg were infused into
the patient. GVHD prophylaxis consisted of cyclosporine, methotrexate, and
steroids. The patient initially did well with neutrophil engraftment (ANC>1000/ul)
on day 23. On day 26 a diffuse rash consistent with acute GVHD developed. Despite
aggressive treatment with high dose steroids, tacrolimus and Cellcept, grade IV
GVHD involving skin, GI tract and liver developed and progressed. The patient
expired on day 46. Retrospectively, patient and donor were sequenced for the A and
B loci using automated four color ﬂuorescent sequencing and dye terminator chem-
istry. Exons 2, 3 and 4 of the A locus and exons 2 and 3 of the B locus were
sequenced. Results of the patient followed by donor are shown below:
A*0301 A*3001 B*0702 B*4402
A*0301 A*3004 B*0702 B*4403
These results demonstrate additional mismatching at one A and one B locus as
well the known mismatch at the C locus. This patient and donor were a three anti-
gen mismatch for class I alleles, likely resulting in the severe acute GVHD
observed. DNA typing of class I antigens should be performed on prospective
donors before unrelated donor BMT for CML, especially when antigens with mul-
tiple alleles (such as A30 and B44) are found on serologic typing and when other
disparities (such as C mismatch) are known.
THE QUALITY OF STEM CELL (SC) COLLECTION PREDICTS FOR MORE
RAPID ENGRAFTMENT FOLLOWING STEM CELL TRANSPLANTATION (SCT).
J.R. Schriber, J.C. Alvarnas, D Boudreau, E Simpson, A. Dagis, S.J. Forman, I. Sniecinski. City
of Hope and City of Hope Samaritan BMT Program. Duarte CA, and Phoenix AZ.
SCT is increasingly used to treat malignant disease. Typical collection goals are
a minimum CD 34 cell count of 2-3.0 x 106/Kg, although some studies have sug-
gested that collecting higher CD 34 numbers may hasten platelet count recovery.
Little information is available on the “quality” of SC collections. To investigate
this, we examined patients (pts) who underwent apheresis with a collection goal of
4-5 x 106/Kg CD 34 cells to determine whether pts who achieved this goal in ( 2
apheresis procedures (group 1) engrafted faster than pts who required more than 2
apheresis (group 2). Fifty ﬁve pts have undergone apheresis and subsequent SCT
over the past 18 months. Twenty three of these met their SC goal in ( 2 collections
while 32 required more than 2 collections. Pt diagnosis were equivalent and their
was no difference in the transplant regiments between the 2 groups. The median
number of CD34 cells was signiﬁcantly higher in group 1. Neutrophil and platelet
engraftment were signiﬁcantly faster in group 1. It is unclear whether this differ-
ence is attributable to a difference in quality or whether the higher number of CD
34 cells infused into patients in group 1 accounts for the more rapid engraftment.
Previous studies have shown no difference in engraftment beyond a threshold dose
suggesting that quality in addition to quantity of cells collected is important in
achieving rapid engraftment. Further study on why some patients mobilize rapidly
appears warranted.
GROUP 1 ( 2 APHERESIS) GROUP 2 P VALUE
(N=23) (N=32)
Diagnosis




Collection # (median) 2 4
CD 34 #/kg (median x 106/kg) 8.1 (3.6-28.3) 4.6 (2.2-29.6)
0.003
Engraftment (days)
ANC > 500 9(6-10) 10(7-16)
0.003
Plt > 20 10(9-20) 12(9-40)
0.002
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PROSPECTIVE NEUROCOGNITIVE ASSESSMENT FOLLOWING BONE
MARROW TRANSPLANTATION: PART II. INFANTS.
Shimoda, KC, McCabe, MA, Schuman, WB, Dinndorf, PA Children’s
National Medical Center and George Washington University School of
Medicine and Health Sciences, Washington, DC
Bone marrow transplantation (BMT) includes preparative regi-
mens which may be toxic to the developing central nervous system.
Infants and children under the age of three may be at particular risk
for neurotoxic effects of preparative regimens due to the vulnerable
nature of the nervous system in early development. Longitudinal
data are presented for 41 children under the age of 3 who under-
went BMT for treatment of leukemia or other blood disorders.
Patients have been followed prospectively with developmental
and/or cognitive testing (Bayley, Bayley-II, McCarthy Scales) at
baseline, 6-months post-BMT, and 18-months post-BMT. Overall,
young children’s developmental levels remain within normal limits
at 6-months post-BMT, with signiﬁcant declines in developmental
level demonstrated by 18-months post-BMT. Ongoing evaluation
of these patients includes follow-up assessments at 36 months and
60 months post-BMT.
PROGENIPOIETIN, A POTENT HEMTOPOIETIC STEM CELL MOBILIZ-
ING AGENT.
P.R. Streeter, J.M. Mulcahy*, J.P. McKearn, W.H. Fleming*. Division
of Hematology and Medical Oncology, Oregon Health Sciences Universi-
ty, Portland, OR, USA*, and G.D. Searle, A Monsanto Co., St. Louis,
MO, USA
Progenipoietin (ProGP) is a dual receptor agonist which activates
both the ﬂt-3 and the G-CSF receptors. We evaluated the capacity
of ProGP to mobilize transplantable hematopoietic stem cells
(HSC) and progenitor cells into the peripheral blood (PB) of nor-
mal mice. To study the functional activity of circulating HSC, the
potential of unfractionated PB to protect lethally irradiated (1100
cGy) congenic recipients was determined. Donor C57B1/6 mice
were injected daily for 5 days with either ProGP or PBS/BSA. As
little as 5 uL of unfractionated PB from ProGP treated donors pro-
tected 100% of lethally irradiated recipients and 1 uL of PB res-
cued 80% of recipients. In contrast, 100 uL of PB from PBS/BSA
treated donors failed to protect irradiated recipients. The PB of all
radioprotected recipients of donor cells from ProGP treated ani-
mals showed donor-derived (Ly5.2) multilineage hematopoietic
reconstitution. In serial transplantation studies, bone marrow from
radioprotected chimeric recipients of ProGP treated donors was
harvested and then transplanted into lethally irradiated congenic
recipient mice (Ly5.1). These secondary recipients demonstrated
donor-derived B220+ cells, CD3+ cells and Mac-1+/Gr-1+ cells in
PB indicating the engraftment of functional HSC. The engraft-
ment potential of ProGP PB HSC was also confirmed using a
competitive repopulation assay. These results indicate that the
administration of ProGP leads to the mobilization of substantial
numbers of transplantable HSC in normal mice.
HIGHER DOSE G-CSF CAN SALVAGE PATIENTS (PTS) WHO FAIL TO
MOBILIZE PERIPHERAL BLOOD PROGENITOR CELLS (PBPC) WITH
STANDARD DOSE G-CSF.
I. Sniecinski, J. Schriber, J.Alvarnas, G. Somlo, S. Forman, City of
Hope and City of Hope-Samaritan BMT Program, Duarte, CA and
Phoenix, AZ
Fifteen to 20% of pts mobilize poorly following standard G-CSF
dose (10 (g/kg/day). In this study we evaluated whether higher doses of
G-CSF may salvage these poor mobilizers. Between Jan. and Oct. 1998,
50 pts failed to collect adequate CD34+ cells in response to a standard
G-CSF dose. PBPC collection began on Day 5 of G-CSF(10
(g/kg/day). CD34+ cells were measured in PBPC product using the
ISHAGE protocol. Pts with insufﬁcient CD34+ cell yields (<1x106/kg)
after the ﬁrst 3 collections, received augmented doses of G-CSF (10
(g/kg/BID) until sufﬁcient CD34 cells were harvested. Twenty-nine
were males and 21 females. The median age was 34 (range 11-56).
Diagnoses were: NHL (14), MM (11), HD (8), Breast Carcinoma (8),
Acute Leukemia (4), other (4). Table 1 summarizes WBC and CD34
cell yields in PBPC concentrate.
PBPC Concentrate Before G-CSF After G-CSF Fold
Increase Parameters Increase Increase
WBC(x109) 13.3 (0.8-52) 19.2 (6.2-55) 1.4
CD34(%) 0.10 (0.01-0.20) 0.33 (0.06-1.23) 3.3
CD34x106/kg 0.21 (0.01-0.69) 0.82 (0.09-3.15) 3.8
Forty-eight (96%) pts had an increase in CD34+ cells after G-CSF
dose escalation. Median increase in WBC yield per apheresis was 1.4
fold. Median increase in the % and total CD34+ were 3.3 and 3.9 fold,
respectively. Following G-CSF dose increase, a median 6 (2-16) addi-
tional aphereses were required to obtain the target CD34 cell dose for
transplantation. Side effects from G-CSF dose escalation included bone
pain and headache. No grade 4 toxicity was noted. We conclude that
G-CSF dose escalation in pts who mobilize poorly with standard dose
G-CSF is an effective strategy for mobilization of CD34+ cells.
USE OF S-59 UVA TREATED LEUKOCYTES FOR ALLOGENEIC CELLU-
LAR IMMUNE THERAPY (ACIT):
Sohel Talib, Aaron Reames, Weiqun Liu, Julia McLaughlin and John E Hearst.
Cerus Corporation, Concord, CA. and Department of Chemistry, University of Cal-
ifornia, Berkeley, CA
The proliferation of donor T cells in vivo is the principal cause of
GVHD during allogeneic stem transplantation (Allo-SCT).
New strategies are needed to control T-cell alloreactivities in order
to make allogeneic transplantation safer and more effective. This study
was carried out to test the hypothesis that treatment of human leuko-
cytes in vitro with S-59 and UVA can modulate the T cell proliferation
without the loss of their immunological activities. Thus, human leuko-
cytes when treated with varying doses of S-59 + UVA and then activat-
ed by either the mixed lymphocytes reaction (MLR) or by anti-CD3
stimulation showed dose dependent inhibition in lymphocyte prolifer-
ation. At optimum dose (15 nM and 3 J/cm2) where proliferation of
lymphocytes was inhibited >95% cytokine synthesis (IL-2 and (-IFN)
and cell surface antigen expression (CD25 and CD69) remained unef-
fected. In addition, cytotoxic T cell activity (CTL) of the photochemi-
cally treated cell population is retained. Thus the density of S-59
adducts in the genome at the most effective addition doses are sufﬁ-
cient to inhibit DNA synthesis, and yet infrequent enough to allow for
the transcription of most genes, allowing for the induction of activated
gene expression. Comparison of the concentration dependence of S-59
photoaddition with other psoralens [aminomethytrimethylpsoralen
(AMT) and 8-methoxypsoralen (8-MOP)] established that S-59 pho-
toaddition is unique in its degree of speciﬁcity for DNA modiﬁcation,
thus reducing other forms of non-speciﬁc damage associated with all
photochemical processes. Detailed measurements of addition frequen-
cies in lymphocyte genomic DNA were measured by use of radiola-
belled psoralens and by an assay based on the inhibition of PCR by the
photoadducts. The density range of adducts promoting the desirable
T-cell functions was determined to be 1 to 10 per million base pairs. In
conclusion, S-59/UVA photochemical treatment of leukocytes pro-
vides a novel means of controlling the T-cell alloreactivity during allo-





CHANGING TREND OF PAEDIATRIC BMT IN SINGAPORE
A.M. Tan2, P. Tan1, M.Y. Chan2. W. Hwang1. Dept. of Haematology1, Singapore
General Hospital and Division of Haematology/Oncology2, Dept. of Paediatrics, KK
Women’s & Children’s Hospital
Between 7/1985 and 9/1998, 28 children between age of 2 to 12.5 years,
mean age 8.1 years, underwent auto/allogenic HSCT for various diseases
(ALL=10, AML=5, CGL=4, SAA=4, Thal=3, Fanconi=1, NHL=1). The
source of the stem cell was BM=24 and PBSC=4. Types of HSCT were
Auto=3, Allo/sib=18 (64%) and MUD=7 (25 %). Conditioning regimen
varies, ALL and lymphoma had CY/TBI(7) or BuCy(4), AML had
Cy/Mel(2) or Bu/Cy(3), SAA and Fanconi had Cy/ATG ( TNI(5), Thal had
Bu/Cy(3). MNC cell dose ranged from 1.62 to 30.1x10(8)/kg (mean
5.76x10(8)/kg). GVHD prophylaxis regimen consisted of cyclosporin A &
Methotrexate. Neutrophil engraftment was successful in 25/27 patients
(92%), range 9 to 44 days. Nonengraftment occured in 2/27 patients (17%),
in 1 SAA & 1 Thal. 1 patient died of mycosis at Day 10 and before engraft-
ment and was not evaluated. Overall survival 12/28=43% (Day from BMT
ranged 55 to 1585 mean=766 days). Of the 16/28 patients died (57%), 6/16
died from transplant related complications and 3/6 were MUD transplant,
the other 10/16 died from rejection/relapsed of the illness. 76% (19/25) allo-
genic transplant had AGVHD, only 3 had severe GVHD grade 3 or > and all
these 3 died from complication of GVHD or Rx or disease relapse. Chronic
GVHD occured in 6/25 patients (24%).
Prior to 1994, supportive care was not optimal and patients were in poor
clinical conditions with active leukemia or infection before transplant and
hence all 9 cases of HSCT (2 auto, 7 allo) died. 1 died from transplant relat-
ed complication and 8 died from relapse/rejection. Since 1994 to early 1998,
a specialised adult BMT team, with input from paediatricians, performed 17
HSCT; 7MUD & 10 allogenic transplant. 10 survivals (59%) ranged from
day 291 to 1585 (mean days of 927). Of 7 died, 5 had transplant related com-
plications and 2 had disease relapse. (4 of these were MUD transplants).
Since early 1998, 4 HSCT were performed in the new Children’s Hospital 2
of which were too early to analyse.
ANTIEMETIC EFFICACY OF THREE SERONTONIN ANTAGONISTS (SA)
DURING HIGH-DOSE THERAPY (HDT) AND AUTOLOGOUS STEM CELLS
TRANSPLANTATION (ASCT), A PROSPECTIVE RANDOMIZED STUDY.
J Slaby, M Tmeny, B Prochazka, P Klener. 1st Department of Medicine,
General University Hospital of Charles University, Prague, CR
The aim of the study: To compare the antiemetic efﬁcacy of three par-
enteral SA during conditioning regimen prior to ASCT.
Patients and methods: 45 malignant lymphoma patients (median age 38 y
M:F 30:15) undergoing regimen BEAM and ASCT, were randomized for
granisetron 3mg once a day (G), tropisetron 5mg once a day (T) or
ondansetron 8mg twice a day (O) administration. The groups were compara-
ble as to age, sex and experience of previous nausea and/or vomitus. The
patients recorded the duration of nausea and numbers of vomitus for 10 d.
Failure of antiemetic therapy was deﬁned as a nausea  4 hours and/or  3
vomitus/24 h and failure of emesis control  3 vomitus/24 h. Both the period
of chemotherapy (6 days) and the follow-up period (10 days) were evaluated.
Results: The antiemetic therapy response (no failure of therapy) was
observed in 76% and 49%, the emesis control was attained in 98% and 73%
of patients during the chemotherapy and follow-up periods, respectively.
The efﬁcacy of three SA was comparable during the chemotherapy period.
However, the antiemetic therapy response and emesis control were signiﬁ-
cantly better in the granisetron and in tropisetron groups compared to the
ondansetron group during follow-up period (10 d).
TABLE: GTOP
failure of antimet. Th - 6 d 5(33%) 2(13%) 4(27%) 0.40
failure of antiemet. Th - 10d 7(47%) 5(33%) 12(80%) 0.03
failure of emesis contr. - 10 d 4(27%) 1(7%) 7(47%) 0.04
Conclusion: All three SA have identical efficacy during high-dose
chemotherapy (BEAM) administration. Tropisetron and granisetron howev-
er, provide better antiemetic control compared to ondansetron during
postchemotherapy period, when factors other than chemotherapy along can
inﬂuence emesis and nausea induction.
GM-CSF BASED TUMOR CELL VACCINES ELICIT POTENT ANTITUMOR
IMMUNITY AFTER ALLOGENEIC TCD BMT.
Takanori Teshima*, Nicolas Mach**, Yani S. Brinson*, Geoffrey R. Hill*,
Glenn Dranoff**, and James L.M. Ferrara#. Departments of *Pediatric
Oncology and **Adult Oncology, Dana-Farber Cancer Institute, Harvard
Medical School, Boston, MA, #Departments of Internal Medicine and
Pediatrics, University of Michigan Cancer Center, Ann Arbor, MI
Immunotherapy offers an attractive approach to eradicating minimal resid-
ual disease (MRD) after BMT, and we have explored an immunization strate-
gy using irradiated B16 melanoma cells (H-2b) that were engineered to
secrete GM-CSF (B16-GM vaccine) to induce speciﬁc immunity to wild type
B16. Allogeneic BMT was performed using donor and recipient strains that
differed by either minor and MHC antigens (SJL((B6SJLF1) or minor anti-
gens alone (LP((B6). Recipients were given 5 x 106 donor bone marrow and 1-
2 x 106 donor T cells following 1100cGy TBI. Syngeneic and T cell-depleted
(TCD) donors were used as non-GVHD controls. B16-GM vaccine was
injected sc.6 weeks after BMT and animals were subsequently challenged with
wild type B16 2-4 weeks later. All unvaccinated animals showed 0% tumor
free survival (TFS) by 3 weeks after tumor challenge and their splenocytes did
not respond to B16 stimulators in vitro. B16-GM vaccine provided potent
antitumor immunity after TCD BMT (77% TFS) and it was at least as pow-
erful as that observed after syngeneic BMT (54% TFS). In vitro analysis of
splenocytes one week after vaccination revealed marked proliferation and
cytokine production (GM-CSF, IFN-(, IL-2, IL-4, IL-5, IL-10) to B16 cells
in vitro. In contrast, vaccination was less protective in recipients given allo-
geneic T cells with mild GVHD (27% TFS) and afford no protection in ani-
mals with moderate GVHD (0% TFS). Thus, the magnitude of antitumor
immunity was inversely correlated with the severity of GVHD, suggesting
that GVHD-associated immunosuppression limits the protective effect of
vaccinations after allogeneic BMT. This result demonstrates that immuno-
logic reconstitution after TCD BMT can provide signiﬁcant protection of the
immunosuppression if GVHD is prevented. This antitumor immunity was
long-lasting since 100% (4/4) of the TCD recipients survived rechallenge
with wild type tumor 5 months after vaccination. Surprisingly, vaccination did
not exacerbate GVHD in either BMT model. These data suggest that the
combined approach of TCD (to prevent GVHD) followed by GM-CSF vac-
cination (to eradicate MRD) may offer a novel strategy to improve disease
free survival in patients receiving allogeneic BMT for malignancy.
EFFECT OF PHOTOCHEMICAL TREATMENT WITH S-59 PSORALEN
AND UVA LIGHT ON GVH AND GVL REACTIVITY OF ALLOGENEIC
MURINE T-CELLS.
Robert L. Truitt, Bryon D. Johnson, Sohel Talib and John E. Hearst. Department
of Pediatrics and Cancer Center, Medical College of Wisconsin, Milwaukee, WI,
Cerus Corporation, Concord, CA, and Department of Chemistry, University of Cal-
ifornia, Berkeley, CA
The purpose of this study was to analyze the effects of photochemical
treatment ex vivo with S-59 (a psoralen) and UVA light (S-59 PCT) on
graft-vs-host (GVH) and graft-vs-leukemia (GVL) reactivity in murine mod-
els of MHC-mismatched and presensitized MHC-matched BMT. S-59
PCT limits the proliferation of donor T-cells by intercalating and crosslink-
ing DNA. The effect of S-59 PCT on T-cells was dependent upon the con-
centration of S-59 and the UVA exposure used (3 to 30 J-nM/cm2). At cer-
tain doses, activated S-59 PCT T-cells secreted cytokines (IL2, (IFN, IL10)
and expressed activation markers (e.g., CD25 and CD69), but showed limit-
ed proliferation in vitro. Using an MHC-mismatched model of T-cell
depleted BMT (C57BL/6 into AKR; H2b into H2k), we found that the inci-
dence and intensity of GVH reactivity of PCT-treated cells was S-59, UVA,
and T-cell-dose-dependent. Addition of S-59 PCT T-cells to TCD MHC-
mismatched BM resulted in elimination of residual host cells, conversion to
complete and stable donor chimerism in T, B and monocytic lineages, and
improved survival rates. Chimeras given S-59 PCT T-cells resisted a chal-
lenge of AKR acute T-cell leukemia cells, indicating that GVL reactivity was
not lost. In the absence of the S-59 PCT T-cells (T-depleted BM only),
higher rates of mixed chimerism, graft failure and leukemia-related deaths
were observed. Lethal GVHD developed in control mice given untreated T-
cells or cells treated with S-59 or UVA alone. To assess the effect of S-59
PCT on presensitized donor cells, an MHC-matched model (B10.BR into
AKR; H2k into H2k ) was used. Presensitization of MHC-matched donors to
host alloantigens (by multiple i.p. injections of host splenocytes) induced
hyperacute GVH reactivity, and more intense S-59 PCT treatment was
required to prevent or diminish GVH reactivity. With some treatment regi-
mens, S-59 PCT cells retained GVL reactivity and showed significantly
reduced GVH reactivity. When S-59 PCT treatment was sufﬁcient to elimi-
nate GVH reactivity of presensitized donor T-cells, the GVL effect also was
eliminated. These results indicate that S-59 PCT treatment is a potential
approach to controlling T-cell alloreactivity in vivo without loss of their ben-
eﬁcial activities, but that the therapeutic window in mice is narrow.
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FLUDARABINE-BASED CONDITIONING FOR ALLOGENEIC TRANSPLAN-
TATION IN A 40 YEAR OLD DIALYSIS PATIENT WITH SICKLE CELL
DISEASE.
Koen van Besien M.D, Amelia Bartholomew M.D., Wendy Stock M.D,
David Peace M.D, Steve Devine M.D, Dori Scherr M.S., Jeff Sossman
M.D and Ronald Hoffman M.D- University of Illinois at Chicago,
Chicago, Illinois, 60612
Background. Although allogeneic transplantation can be cura-
tive for patients with sickle cell disease, the toxicity of conditioning
regimens has precluded its use in adults with signiﬁcant end-organ
damage. Newer conditioning regimens have been developed that
are considerably less toxic and that may broaden the applicability of
allogeneic transplantation in this disorder.
Case report. We report the case of a 40 year old woman with
sickle cell disease and extensive end-organ damage. She had suf-
fered numerous pain crises, had been extensively transfused, had
developed multiple red blood cell antibodies and was suffering
from end-stage renal failure. This patient underwent an allogeneic
stem cell transplantation from her HLA-identical sibling after con-
ditioning with fludarabine, ATG and melphalan. Engraftment
occurred promptly. More than 9 months after transplantation, the
patient continues to be free of sickle cell disease and in good condi-
tion.
Conclusion The use of conditioning regimens with limited toxi-
city allows the use of allogeneic transplantation in adults who have
end-organ damage and constitutes a curative treatment for highly
symptomatic patients.
A RANDOMIZED, PROSPECTIVE COMPARISON OF ALLOGENEIC BONE
MARROW (BM) AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC)
TRANSPLANT IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES:
AN UPDATE.
AC Vigorito, AM Azevedo, KAB Eid, FJP Aranha, GB Oliveira, MEP Correa,
ECM Miranda, ARC Reis, JFC Marques Jr, I Lorand-Metze, WM Azevedo and
CA Souza. BMT Unit, State University of Campinas, SP, Brazil
We present updated results of a prospective, randomized study
comparing both techniques with regards to engraftment, acute and
chronic graft versus host disease (GVHD) and survival. Since Feb
95, 50 patients with hematologic cancers received Human Leuko-
cyte Antigens (HLA) -identical sibling BM (group A) or PBPC
(group B) transplants. Evaluable patients at the end were 24 (A) and
23 (B). Median age was 36 years (17-56) in A and 29 years (7-51) in
B. Conditioning was Busulfan-Cyclophosphamide (Bu-Cy2);
GVHD prophylaxis was cyclosporine-metrotrexate (CSA-MTX).
PBPC were harvested after 5 days of G-CSF 10	g/g/d. The medi-
an content of CD34+ cells x106/Kg was 5.09 (1.1-17.5) in A and
5.75 (1.2-71.6) in B (p=0.2). Median of days for an absolute neu-
trophils count (ANC) >0.5 x109/l was 18 (13-30) in A and 15 (11-
25) in B (p=0.04). Platelet counts >20 x109/l occurred at +19 (10-
40) in A and +13 (9-36) in B (p=0.001). Median of hospital
discharge was +26 (18-69) in A and +21 (16-42) in B (p=0.1). The
incidence of acute GVHD of grade (2 was 21,1% (A) and 26,3%
(B) (p=0.5). The incidence of chronic GVHD was 50% with BM
and 61.1% with PBPC (p=0.76); extensive disease was present in
50% and 100%, respectively (p=0.01). The relapse rate was 8.3%
(2/24 pts) in A and 17.3% in B (4/23 pts), at a median follow-up of
719 (106-1314) and 411 (141-1349) days, respectively. The esti-
mates of overall survival at 1300 days are 44% and 53% respective-
ly (p=0.64) and disease free survival, 42% and 59% (p=0.27). PBPC
resulted in faster engraftment, the incidence of acute and chronic
GVHD was similar but the severity of chronic GVHD remain
higher with PBPC. No differences in survival were detected so far.
PARMACOKINETICS OF INTRAVENOUS BUSULFAN IN HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT).
W.P Vaughan, P. Cagnoni, H. Fernandez, W. Hu, A. Kashyap, V. Gain, J. Wingard, S.
Tarantolo, B.S. Andersson. U of AL at Birmingham, U of CO, U of Miami, Stanford U,
City of Hope, U of FI, MD Anderson Cancer Center
Oral busulfan (BU) is a well-established ablative component of many hematopoi-
etic stem cell conditioning regimens. However, many studies have demonstrated
wide pharmacokinetic variability. BU levels can be an important determinant of
regimen-related toxicities or graft rejection. An IV form of BU (BusulfexTM) has
been developed which reduces the variability of BU AUC. Herein, we will report
the pharmacokinetic data of 103 patients that participated in one of two Phase II
open-label, multi-center trials using Busulfex (0.8 mg/kg Q6h x 16) and cyclophos-
phamide (60 mg/kg/d x 2) as the preparative regimen for HSCT (42 auto and 61
allo). Sixty-three patients were male and 43 were female. Transplants were per-
formed for acute leukemia (33), CML (17), lymphoma (45), and MDS (9). The
patients ranged in age from 13 to 63 (median = 34 and 37.5 for auto and allo
patients respectively). Plasma levels of BU were analyzed from 15 min through 6
hrs after the ﬁrst, ninth and thirteenth dose of Busulfex. Dose 1 AUC was extrapo-
lated to inﬁnity (AUCinf) and dose 9 and 13 AUC were corrected for steady state
(AUCss). The target AUCinf below 1500 (Mol-min for Busulfex dose 1 was
achieved for 88 (90%) of the 98 patients with fully evaluable day 1 and day 9 phar-
macokinetics representing drug exposure generally considered safe in terms of risk
of VOD. This was achieved with a mean AUCinf for dose 1 of 1141 (Mol-min (sd
324). The mean dose 1 AUC for the autologous patients was 1144 (Mol-min (sd
222) and for the allogeneic patients was 1106 (Mol-min (sd 318). The pharmacoki-
netic proﬁle of the ﬁrst Busulfex dose predicted with good precision the steady-
state AUC of the ninth Busulfex dose. The mean dose 9 AUC was 1225 (Mol-min
(sd 216) for the autologous patients and 1167 (Mol-min (sd 224) for the allogeneic
patients. All patients engrafted (ANC >0.5 x 109/L) with median days to engraft-
ment for auto of 10 days (range 8 to 19) and for allo 13 days (range 9 to 29). There
was no late graft failure or rejection. Freedom from progression, progression free
survival, and overall survival compare favorably with comparable risk groups of
oral busulfan treated patients at a median follow up of almost one year. This com-
parable effectiveness and improved safety proﬁle of the Busulfex substitution for
oral busulfan is presumably due to the narrow std deviation achieved with this
preparation. The reduced inter patient and inter dose variability of Busulfex com-
pared with oral busulfan will make accurate pharmacokinetic based therapy with
limited sampling strategy feasible and busulfan based transplantation safer and
more effective.
PHASE II TRIAL OF INTRAVENOUS BUSULFAN (IV BU) AND
CYCLOPHOSPHAMIDE (CY) IN PEDIATRIC PATIENTS: PRELIMINARY
PHARMACOKINETICS.
D.A. Well, K.W. Chan, M.R. Klemperer, R. Kadota, and M. Kletzel for the Pedi-
atric Blood and Marrow Transplant Consortium, Saint Louis University, St. Louis,
MO, M.D. Anderson Hospital, Houston, TX All Children’s Hospital, St. Peters-
burg, FL, Children’s Hospital of San Diego, CA, and Children’s Memorial Hospi-
tal, Chicago, III
Oral busulfan is a well established component of preparative regimens
for hematopoietic stem cell transplant (HSCT). An intravenous formu-
lation would eliminate oral administration and ﬁrst-pass hepatic clear-
ance as variables in drug dosing; issues especially problematic in the
pediatric population.
In a Phase II open-label, multi-center trial, seven pediatric patients
have undergone HLA -matched sibling allogeneic HSCT after a condi-
tioning regimen with a new formulation of IV BU (BusulfexTM) and
CY. IV BU was given a dose of 0.8 mg/kg based on actual body wt q6h
x 16 doses, followed by CY 50 mg/kg iv q24 h x4 doses. The median
age was 9y (3-15y), with median wt of 22 kg (16-49 kg). Transplants
were performed for AML (2), ALL (1), MDS (1), thalassemia (2), and (-
mannosidosis (1). Plasma levels of BU were analyzed after 1st and 9th
doses of IV BU. If the ﬁrst dose AUC did not fall within the target
range of 900-1500 (Mol-min, doses 7-16 were adjusted. The median
dose 1 and dose 9 AUC levels were 909 (Mol-min (range 450 to 1306)
and 1169 (Mol-min (range 885-1508), respectively. No dose adjust-
ments were needed for 3 children > 25 kg. Lower AUCs were noted for
the smaller children, with 3 of 4 requiring an increase in dose. 7/7
engrafted by 12 d (range 11-14d) and no unique toxicities were noted.
Two patients had mild VOD which was resolved. 5/7 are alive and well,
in remission or with correction of genetic disorder at 3 - 12mo post
HSCT (2 deaths - recurrent leukemia (1), GVHD(1)).
IV BU (BusulfexTM) results in relable pharmacokinetics with a dose of
0.8 mg/kg in children > 25 kg, with associated engraftment and no
unexpected toxicity. The study is continuing to enroll smaller children
to deﬁne dosing in this group.





TOXICITY OF SINGLE DAILY DOSE (SDD) GENTAMICIN IN STEM CELL
TRANSPLANT (SCT) RECIPIENTS.
D.I. Warkentin, C. Ippoliti, J. Bruton, K. Van Besien, and R. Champlin;
Vancouver Hospital and Health Science Center, Vancouver, B.C., Canada and
The University of Texas, M.D. Anderson Cancer Center, Houston, TX,
U.S.A.
Published clinical trials suggest SDD aminoglycosides in combination
with other antimicrobial agents are sage and effective in SCT recipi-
ents. Several months after the institution of SDD gentamicin as part of
our treatment for febrile neutropenia was noted ototoxicity in several
patients (pts). This ﬁnding prompted an immediate evaluation to deter-
mine incidence, and risk factors associated with the administration of
SDD gentamicin. Medical records of all adult SCT recipients who
received SDD gentamicin for the treatment of neutropenic fever during
a two month period were evaluated. Thirty-three patients, mean age 42
years (range 19-61 years), received gentamicin 5mg/kg/day. Mean dura-
tion of therapy was 7 days (range 3-32 days). All patients received van-
comycin and 17 received cisplatinum. All had normal renal and otologic
function prior to therapy. Serum gentamicin levels were monitored
only when renal function deteriorated. One patient (3%) developed
nephrotoxicity, deﬁned as rise in serum creatinine (2x baseline. Four
patients (12%) developed clinically significant ototoxicity. All four
patients had normal serum creatinine concentration before and during
therapy. The mean duration of gentamicin in patients who developed
ototoxicity was 20 days compared to 9 days in patients who did not
experience ototoxicity (p=0.001). The mean duration of gentamicin
therapy prior to the onset of symptoms was 12 days (range 3-19 days).
Four patients developed decreased hearing. In only one of these
patients did these auditory symptoms resolve with drug discontinuation.
Two of these 4 patients also developed severe vestibular toxicity which
did not resolve with drug discontinuation. SDD gentamicin was associ-
ated with clinically signiﬁcant ototoxicity in 12% of our patients. One
must be cognizant of the increased risk of irreversible ototoxicity when
administering SDD gentamicin for a prolonged duration to adult SCT
recipients.
SUCCESSFUL NONMYELOABLATIVE ALLOGENEIC STEM CELL GRAFT
IN A PATIENT WITH AML AND PROGRESSIVE PULMONARY ASPERGILLOSIS.
CO Xun, PA McSweeney, VC Broudy, JA Thompson and R Storb. Fred Hutchinson
Cancer Research Center (FHCRC) and University of Washington, Seattle, WA
Active aspergillus infection is usually a contraindication for conventional
high-dose hematopoietic stem cell transplant (HSCT) at the FHCRC given
that all patients (pt) so treated in the past have died from progressive
aspergillosis. Here we report a successful nonmyeloablative allogeneic
HSCT as a rescue procedure in a 49 year old pt who had prolonged marrow
aplasia and active pulmonary aspergillus infection after induction chemother-
apy. The pt presented with AML/M1 with 85% CD13+, CD33+, CD34+
blasts in the marrow and received two cycles of induction chemotherapy
(Ara-C 200mg/m2/d 1-7 and Ida 12mg/m2/d 1-3) due to persistent disease.
His marrow became aplastic and he developed pulmonary nodular
aspergillus lesions after being neutropenic with 0 neutrophils for 49 days
despite treatment with amphotericin B and G-CSF. An HLA-matched non-
myeloablative HSCT was given as a rescue procedure for prolonged marrow
aplasia. The pt received TBI 200 cGy on day 0 followed by 10x106/kg G-
CSF mobilized CD34+ cells from his brother after conﬁrmation of marrow
aplasia without evidence of leukemia and neutropenia for 61 days with rapid
left upper lobe consolidation of the lung due to aspergillosis. Post transplant
immunosuppression included cyclosporine (CSP) day-1 to 80+ and
mycophenolate mofetil (MMF) day 0-27. He engrafted with an ANC>500 by
day +8 and become platelet and red cell transfusion independent by day +13.
On day +14, 99% of neutrophils and 70% of lymphocytes were donor origin.
The day +28 marrow exam showed 99% donor cells with no evidence of
leukemia. The pt was discharged to outpatient care by 3 weeks after trans-
plant. He is now 80 days after transplant with a stable donor graft and no evi-
dence of GVHD on CSP. The anti-fungal treatment was changed to oral
viroconazol after total dose of 2.1 gram of amphotericin B treatment. Pul-
monary lesions are slowly resolving on follow-up imaging studies. In conclu-
sion, a successful allo-HSC graft was achieved after low dose TBI and
CSP/MMF to control both host vs graft and graft vs host reactions in a pt
with chemo-induced prolonged marrow aplasia and progressive pulmonary
aspergillosis. The transplant was associated with minimal toxicity and the
pulmonary aspergillosis infection is slowly resolving. This procedure should
be prospectively tested as a means to rescue pts suffering from refractory
chemo-induced marrow aplasia.
ATG AS PART OF THE CONDITIONING IN MUD BMT-CLINICAL AND
BIOLOGICAL RESULTS.
R. Schwerdtfeger, H. Baurmann, N. Bonnefoy-Berard*, C. Kreißig,
J.P.Revillard*; BMT Center DKD, Wiesbaden, GERMANY, *INSERM U80,
Hôpital E. Herriot, Lyon, FRANCE
Despite the increasing use of ATG for conditioning in MUD BMT little is
known about its biological effects and inﬂuence on clinical outcome in this
context. We present our clinical as well as the pharmacokinetic and lympho-
cyte (ly) reconstitution data generated in 50 consecutive MUD transplants.
34 males and 16 females, median (md) age 34y, received unmanipulated bone
marrow (BM) from matched (n=43) and DRB1 mismatched (n=7) voluntary
donors for CMLCP (n=20), CMLBC (n=3), high risk/relapsed AML (n=16),
ALL/NHL (n=10) and SAA (n=1) resp. Thymoglobulin* was added to stan-
dard chemo/radiotherapy conditioning from d -5 to -2 at 2.5mg/kg/d (n=40),
3.75mg/kg/d (n=6) or 5mg/kg/d (n=4). 45 patients (pts) engrafted at md of
19d (14-32). 5 pts died before engraftment, 1 pt had 2nd BM failure. Acute
GvHDºII-IV developed in 19 (ºIV in 3), chronic GvHD in 7 pts (4 limited, 3
extended). Probability of survival is 68% in CMLCP and 34% in
AL/NHL/SAA (md observation time 9.5 mo). 24 pts died from infections
(n=9), relapse (n=6), treatment related toxicity (n=4), aGvHD (n=2), cGvHD,
EBV LPD and BM failure (n=1 each). Rabbit IgG (ELISA) and speciﬁc anti-
lymphocyte antibodies (ATG eq) quantiﬁed by ﬂow cytometry can be detect-
ed in pts sera in decreasing concentrations up to 100d after BMT. Ly typing
reveals normal NK cell reconstitution (md of 88% of ly) and prolonged
depression of CD3+ and CD4+ cell counts (md of 101 and 14/(l) at d100,
resp. In selected pts slowly rising CD3+ cells can only be shown after disap-
pearance of ATG from the serum. Initially all CD3+ and a part of CD3 neg-
ative cells are coated by rabbit IgG, with decreasing overall coating from d70
onwards. In addition, decreased CD3 md ﬂuorescence intensity compared to
pretreatment values even after disappearance of ATG from the serum indi-
cates down modulation of surface CD3/TCR possibly further contributing
to immunosuppression and tolerance induction after MUD BMT. Conclu-
sions: In vivo T cell depletion of the graft with ATG results in a high level of
engraftment and low incidence of severe GvHD. Relapses so far are no more
frequent than expected in this high risk population. Profound quantitative
and qualitative depression of T cell function can be demonstrated during the
ﬁrst 100d after MUD BMT.
ETHANOL TOXICITY WITH HIGH-DOSE ETOPOSIDE: A CASE REPORT
IN TWO BONE MARROW TRANSPLANT RECIPIENTS.
JA Williams, PE Kintzel, E Abella, J Klein, R Dansey, C Karanes, R
Baynes; Barabara Ann Karmanos Cancer Institute, Wayne State Universi-
ty, Detroit, MI, USA
This report describes an unexpected and previously unreported
adverse effect of etoposide infusion in two pediatric bone marrow trans-
plant patients. The epipodophyllotoxin etoposide is a topoisomerase II
inhibitor with activity against leukemias, lymphomas, testicular tumors,
neuroblastoma, sarcomas and brain tumors. It is included in several
high-dose chemotherapy regimens used for autologous and allogeneic
bone marrow or stem cell transplantation. Bone marrow transplantation
has allowed greater therapeutic efﬁcacy and circumvented the dose lim-
iting myelosuppression of etoposide, permitting doses 5 to 10 times the
conventional dose. Etoposide is poorly soluble in water therefore
absolute alcohol is present in the formulation at a concentration of
30.5% to solubilize this lipophilic drug. These two patients received a
four hour intravenous infusion of high-dose etoposide (60 mg/kg) in
addition to total body irradiation as preparatory regimen for allogeneic
BMT. During the fourth hour of etoposide administration, both
patients had an acute alteration in mental status consisting of somno-
lence, agitation, and emotional lability in association with an acute
metabolic acidosis. Ethanol intoxication was conﬁrmed in the second
patient with an ethanol level measured at 87 mg/dl. The predicted level
of ethanol would be 165-195 mg/dL minus the amount metabolized
over four hours (67-95 mg/dL). Muscular incoordination is seen with
ethanol levels of <50 mg/dL, while respiratory failure, coma and death
occur with ethanol levels of 400-700 mg/dL. The effects of ethanol
intoxication in these pediatric patients were probably aggravated by
concomitant use of the ancillary drugs diphenhydramine and
lorazepam. Ethanol intoxication should be considered as a rare but
potential serious side effect of high-dose etoposide therapy in pediatric
patients. Consideration should be given to replacement with etoposide
phosphate, a formulation which does not contain alcohol, or prolonga-
tion of etoposide infusion times with careful pharmacologic monitoring.
